US20050132466A1 - Elastomeric glove coating - Google Patents
Elastomeric glove coating Download PDFInfo
- Publication number
- US20050132466A1 US20050132466A1 US10/733,172 US73317203A US2005132466A1 US 20050132466 A1 US20050132466 A1 US 20050132466A1 US 73317203 A US73317203 A US 73317203A US 2005132466 A1 US2005132466 A1 US 2005132466A1
- Authority
- US
- United States
- Prior art keywords
- glove
- elastomeric
- hydrogel
- active agent
- substrate body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000011248 coating agent Substances 0.000 title claims abstract description 62
- 238000000576 coating method Methods 0.000 title claims abstract description 62
- 239000000017 hydrogel Substances 0.000 claims abstract description 72
- 239000013543 active substance Substances 0.000 claims abstract description 63
- 230000000717 retained effect Effects 0.000 claims abstract description 12
- 230000008901 benefit Effects 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 43
- 229920000642 polymer Polymers 0.000 claims description 43
- 239000000758 substrate Substances 0.000 claims description 43
- 239000007864 aqueous solution Substances 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 15
- 238000004132 cross linking Methods 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 239000000178 monomer Substances 0.000 claims description 12
- 229920006173 natural rubber latex Polymers 0.000 claims description 12
- -1 styrene-ethylene-butylene-styrene Chemical class 0.000 claims description 12
- 239000003431 cross linking reagent Substances 0.000 claims description 10
- 239000013536 elastomeric material Substances 0.000 claims description 9
- 125000005395 methacrylic acid group Chemical class 0.000 claims description 9
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 claims description 8
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical class OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000007598 dipping method Methods 0.000 claims description 7
- QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical class OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 claims description 6
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical class CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 claims description 6
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical class C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 claims description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 5
- 229920003048 styrene butadiene rubber Polymers 0.000 claims description 5
- 229920000459 Nitrile rubber Polymers 0.000 claims description 4
- 229920003049 isoprene rubber Polymers 0.000 claims description 4
- 229920001084 poly(chloroprene) Polymers 0.000 claims description 4
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 4
- 229920002379 silicone rubber Polymers 0.000 claims description 4
- 229920006132 styrene block copolymer Polymers 0.000 claims description 4
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims 5
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical class CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 claims 4
- 150000003926 acrylamides Chemical class 0.000 claims 4
- 150000001253 acrylic acids Chemical class 0.000 claims 4
- 229920002554 vinyl polymer Polymers 0.000 claims 4
- 239000011148 porous material Substances 0.000 abstract description 9
- 210000003491 skin Anatomy 0.000 description 18
- 229920000126 latex Polymers 0.000 description 13
- 239000004816 latex Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 10
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 9
- 239000000701 coagulant Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 238000001723 curing Methods 0.000 description 6
- 238000010894 electron beam technology Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 description 5
- 238000005660 chlorination reaction Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000000804 eccrine gland Anatomy 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- 238000004073 vulcanization Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000043261 Hevea brasiliensis Species 0.000 description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 description 2
- 244000141009 Hypericum perforatum Species 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 229920000877 Melamine resin Polymers 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 208000010195 Onychomycosis Diseases 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- FACXGONDLDSNOE-UHFFFAOYSA-N buta-1,3-diene;styrene Chemical compound C=CC=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 FACXGONDLDSNOE-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- IVJISJACKSSFGE-UHFFFAOYSA-N formaldehyde;1,3,5-triazine-2,4,6-triamine Chemical compound O=C.NC1=NC(N)=NC(N)=N1 IVJISJACKSSFGE-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 201000005882 tinea unguium Diseases 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- ROGIWVXWXZRRMZ-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1 ROGIWVXWXZRRMZ-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-L 3-(2-carboxylatoethylsulfanyl)propanoate Chemical class [O-]C(=O)CCSCCC([O-])=O ODJQKYXPKWQWNK-UHFFFAOYSA-L 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical class C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-M 5-oxo-L-prolinate Chemical compound [O-]C(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000906543 Actaea racemosa Species 0.000 description 1
- UMHJEEQLYBKSAN-UHFFFAOYSA-N Adipaldehyde Chemical compound O=CCCCCC=O UMHJEEQLYBKSAN-UHFFFAOYSA-N 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 208000029147 Collagen-vascular disease Diseases 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 206010012441 Dermatitis bullous Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 229920002085 Dialdehyde starch Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 101000583175 Homo sapiens Prolactin-inducible protein Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 102100030350 Prolactin-inducible protein Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000001941 Scleromyxedema Diseases 0.000 description 1
- 208000009163 Sebaceous of Jadassohn Nevus Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 239000002174 Styrene-butadiene Substances 0.000 description 1
- 206010042342 Subcorneal pustular dermatosis Diseases 0.000 description 1
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- OGEAASSLWZDQBM-UHFFFAOYSA-N Temelastine Chemical compound C1=NC(C)=CC=C1CC(C(N1)=O)=CN=C1NCCCCC1=NC=C(Br)C=C1C OGEAASSLWZDQBM-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 206010051446 Transient acantholytic dermatosis Diseases 0.000 description 1
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 1
- 244000250129 Trigonella foenum graecum Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 208000014926 Vesiculobullous Skin disease Diseases 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 201000010272 acanthosis nigricans Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000000040 apocrine gland Anatomy 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 239000010473 blackcurrant seed oil Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 239000010474 borage seed oil Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 208000001969 capillary hemangioma Diseases 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- SZKQYDBPUCZLRX-UHFFFAOYSA-N chloroprocaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl SZKQYDBPUCZLRX-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229940027008 deltasone Drugs 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 239000009588 dong quai Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950005722 flosulide Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- TYNDBNTXKWNGDS-UHFFFAOYSA-N formaldehyde;imidazolidine-2,4-dione Chemical compound O=C.O=C1CNC(=O)N1 TYNDBNTXKWNGDS-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000000687 hydroquinonyl group Chemical class C1(O)=C(C=C(O)C=C1)* 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- UHUFTBALEZWWIH-UHFFFAOYSA-N myristic aldehyde Natural products CCCCCCCCCCCCCC=O UHUFTBALEZWWIH-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- CXJONBHNIJFARE-UHFFFAOYSA-N n-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(F)C=C1F CXJONBHNIJFARE-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 229940053973 novocaine Drugs 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001228 polyisocyanate Chemical class 0.000 description 1
- 239000005056 polyisocyanate Chemical class 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- ODGAOXROABLFNM-UHFFFAOYSA-N polynoxylin Chemical compound O=C.NC(N)=O ODGAOXROABLFNM-UHFFFAOYSA-N 0.000 description 1
- 208000003619 porokeratosis Diseases 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 229940071139 pyrrolidone carboxylate Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229940094944 saccharide isomerate Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000001104 scent gland Anatomy 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000011115 styrene butadiene Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229950005829 temelastine Drugs 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 238000007725 thermal activation Methods 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- QNNALNZLUPVUBO-UHFFFAOYSA-N triaziridine Chemical compound N1NN1 QNNALNZLUPVUBO-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 208000030057 verrucous nevus Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B42/00—Surgical gloves; Finger-stalls specially adapted for surgery; Devices for handling or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/04—Coating
- C08J7/0427—Coating with only one layer of a composition containing a polymer binder
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/04—Coating
- C08J7/046—Forming abrasion-resistant coatings; Forming surface-hardening coatings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/04—Coating
- C08J7/056—Forming hydrophilic coatings
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D19/00—Gloves
- A41D19/0055—Plastic or rubber gloves
- A41D19/0058—Three-dimensional gloves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2321/00—Characterised by the use of unspecified rubbers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2400/00—Characterised by the use of unspecified polymers
- C08J2400/14—Water soluble or water swellable polymers, e.g. aqueous gels
Definitions
- Elastomeric gloves are formed to fit tightly against a user's hand and provide good gripping and tactile characteristics during use.
- elastomeric gloves are normally liquid-impermeable to provide a barrier between the wearer and the environment in which the gloves are used.
- these desired characteristics of elastomeric gloves create a harsh environment for the wearer's skin. For example, perspiration is a common problem for glove wearers, and the resulting moist environment may lead to various skin problems, including, for example, growth of fungi and yeast, as well as bacterial and viral infections of the skin.
- those who utilize elastomeric gloves in the medical field frequently clean their hands with soap or sanitary alcohol formulations. This constant cleaning is harsh on the skin, causing excessive skin dryness that may exacerbate other skin problems.
- an elastomeric glove comprising a substrate body including a layer made of an elastomeric material.
- the substrate body defines an inner surface and an outer surface.
- a coating overlies the inner surface of the substrate body and defines a user-contacting surface of the glove.
- the coating comprises a crosslinked hydrogel network within which is retained an active agent capable of imparting a benefit to a user.
- the active agent is releasable from the network when the coating is contacted with an aqueous environment.
- an elastomeric article comprising a substrate body including a layer made of an elastomeric material.
- the elastomeric material is selected from the group consisting of styrene-ethylene-butylene-styrene block copolymers, styrene-isoprene-styrene block copolymers, styrene-butadiene-styrene block copolymers, styrene-isoprene block copolymers, styrene-butadiene block copolymers, natural rubber latex, nitrile rubbers, isoprene rubbers, chloroprene rubbers, polyvinyl chlorides, silicone rubbers, and combinations thereof.
- the substrate body defines a surface over which lies a coating.
- the coating comprises a substantially water-insoluble, crosslinked hydrogel network within which is retained an active agent capable of imparting a benefit.
- the active agent is releasable from the network when the coating is contacted with water.
- a method for forming an elastomeric glove containing a substrate body and a coating overlying a surface of the substrate body comprises dipping a hand-shaped former into at least one bath containing an elastomeric polymer to form the substrate body of the glove.
- An aqueous solution is applied to the substrate body or the hand-shaped former to form the coating of the glove.
- the aqueous solution contains at least one hydrogel-forming polymer and an active agent.
- the hydrogel-forming polymer is crosslinked to form a hydrogel network, wherein the active agent is retained within the hydrogel network and is releasable therefrom when the coating is contacted with an aqueous environment.
- a method for forming an elastomeric glove containing a substrate body and a coating overlying a surface of the substrate body comprises dipping a hand-shaped former into at least one bath containing an elastomeric polymer to form the substrate body of the glove.
- An aqueous solution is applied to the substrate body or the hand-shaped former to form the coating of the glove.
- the aqueous solution contains at least one hydrogel-forming polymer.
- the hydrogel-forming polymer is crosslinked to form a hydrogel network.
- An active agent is incorporated into the hydrogel network, the active agent being releasable therefrom when the coating is contacted with an aqueous environment.
- FIG. 1 is a perspective view of one embodiment of an elastomeric glove made according to the invention.
- FIG. 2 is a cross-sectional view of the glove illustrated in FIG. 1 taken along a line 2 - 2 ;
- FIG. 3 is a graphic illustration of the results obtained in the Example, in which the absorbance of the dye is shown for various diffusion times.
- the present invention is directed to an elastomeric article, such as a condom or glove, which contains a hydrogel coating.
- a hydrogel coating is capable of improving donning (damp and/or dry) and also imparting certain other benefits to a user of the article.
- the hydrogel coating includes an active agent that is retained within a crosslinked hydrogel network. When the hydrogel coating is exposed to an aqueous environment, it swells, allowing the active agent to diffuse through pores and contact the skin of a user.
- the glove 20 includes a substrate body 24 having the basic shape of the glove.
- the substrate body 24 may generally be formed from any of a variety of natural and/or synthetic elastomeric materials known in the art.
- suitable elastomeric materials include, but are not limited to, S-EB-S (styrene-ethylene-butylene-styrene) block copolymers, S-B-S (styrene-isoprene-styrene) block copolymers, S-B-S (styrene-butadiene-styrene) block copolymers, S-I (styrene-isoprene) block copolymers, S-B (styrene-butadiene) block copolymers, natural rubber latex, nitrile rubbers, isoprene rubbers, chloroprene rubbers, polyvinyl chlorides, silicone rubbers, and combinations thereof.
- S-EB-S styrene-ethylene-butylene-styrene block copolymers
- S-B-S styrene-isoprene-styrene block copolymers
- elastomeric materials that may be used to form the substrate body 24 may be described in U.S. Pat. Nos. 5,112,900 to Buddenhagen, et al.; 5,407,715 to Buddenhagen, et al.; 5,900,452 to Plamthottam; 6,288,159 to Plamthottam; and 6,306,514 to Weikel, et al., which are incorporated herein in their entirety by reference thereto for all purposes.
- the substrate body 24 is formed from natural rubber latex.
- a former is initially dipped into a coagulant bath that facilitates later stripping of the glove from the former.
- the coagulant bath may include calcium carbonate and/or calcium nitrate.
- the coagulant-coated former is dried and subsequently dipped into one or more latex baths.
- the resulting latex layer(s) are then typically leached in water to extract a large percentage of the water-soluble impurities in the latex and coagulant.
- the coated former is then dried to cure (i.e., crosslink) the rubber.
- the glove 20 also includes a coating 26 that is present on an inner surface 28 defined by the substrate body 24 .
- the coating 26 defines a wearer-contacting surface 27 of the glove 20 that contacts the body of the user 22 .
- the coating 26 serves dual purposes in the present invention. Specifically, the coating 26 has a low coefficient of friction that facilitates donning of the glove 20 when the user's hand is either dry or wet, i.e., dry and damp donning. The low coefficient of friction may be imparted through surface texture and/or through the lubricity of the materials used to form the coating 26 .
- another purpose of the coating 26 is to controllably release an active agent contained therein for contacting a user's skin and providing some desired benefit.
- the present inventors have discovered that such dual purposes may be accomplished by forming the coating 26 from a hydrogel within which is retained the active agent.
- any of a variety of polymers may be utilized in the present invention to form the hydrogel.
- the polymer is utilized that is formed from at least one hydrogel-forming monomer that is hydrophilic and water-soluble.
- hydrophilic, water-soluble monomers that may be used in the present invention to form the hydrogel polymer.
- Such monomers include, but are not limited to, vinyl pyrrolidone, hydroxyethyl acrylate or methacrylate (e.g., 2-hydroxyethyl methacrylate), hydroxypropyl acrylate or methacrylate, acrylic or methacrylic acid, acrylic or methacrylic esters or vinyl pyridine, acrylamide, vinyl alcohol, ethylene oxide, derivatives thereof, and so forth.
- hydroxyethyl acrylate or methacrylate e.g., 2-hydroxyethyl methacrylate
- hydroxypropyl acrylate or methacrylate hydroxypropyl acrylate or methacrylate
- acrylic or methacrylic acid acrylic or methacrylic esters or vinyl pyridine
- acrylamide vinyl alcohol
- ethylene oxide derivatives thereof
- the resulting polymers may be homopolymers or interpolymers (e.g., copolymer, terpolymer, etc.), and may be nonionic, anionic, cationic, or amphoteric.
- the polymer may be of one type (i.e., homogeneous), or mixtures of different polymers may be used (i.e., heterogeneous).
- the polymer(s) are crosslinked using any known crosslinking technique, including known ionic or covalent crosslinking techniques.
- a crosslinking agent may be utilized to facilitate crosslinking.
- crosslinking agents include, but are not limited to, polyhydric alcohols (e.g., glycerol); polyaziridine compounds (e.g., 2,2-bishydroxymethyl butanoltris[3-(1 -aziridine) propionate] or triaziridine); epoxy compounds; haloepoxy compounds (e.g., epicholorhydrin); aldehyde compounds (e.g., urea-formaldehyde, melamine-formaldehyde, hydantoin-formaldehyde, glutaraldehyde, glyoxal, malonaldehyde, succinaldehyde, adipaldehyde, or dialdehyde starch); polyis
- Crosslinking may be carried out before, during, and/or after application of the polymer to the surface 28 of the substrate body 24 .
- an aqueous solution containing a crosslinking agent and polymer is applied to the surface 28 .
- the mixture is cured at elevated temperatures.
- crosslinking may also be carried out using other well-known techniques.
- crosslinking may be induced with ionizing radiation, which is radiation having an energy sufficient to either directly or indirectly produce ions in a medium.
- ionizing radiation examples include, but are not limited to, electron beam radiation, natural and artificial radio isotopes (e.g., ⁇ , ⁇ , and ⁇ rays), x-rays, neutron beams, positively charged beams, laser beams, and so forth.
- Electron beam radiation involves the production of accelerated electrons by an electron beam device.
- Electron beam devices are generally well known in the art. For instance, in one embodiment, an electron beam device may be used that is available from Energy Sciences, Inc., of Woburn, Mass. under the name “Microbeam LV.”
- Other examples of suitable electron beam devices are described in U.S. Pat. Nos. 5,003,178 to Livesay; 5,962,995 to Avnery; 6,407,492 to Avnery, et al., which are incorporated herein in their entirety by reference thereto for all purposes.
- crosslinking forms a hydrogel constituted by a three-dimensional network that is substantially water-insoluble.
- the hydrogel when exposed to water, the hydrogel does not dissolve, but instead may absorb a certain amount of water.
- the hydrogel is capable of achieving a water content of from about 20% to about 90%, in some embodiments from about 35% to about 85%, and in some embodiments, from about 50% to about 80%.
- the hydrogel swells, thereby increasing the area between crosslinks to form pores.
- the hydrogel may possess pores having an average size of from about 1 nanometer to about 10 microns, in some embodiments from about 10 nanometers to about 1 micron, and in some embodiments, from about 50 nanometers to about 100 nanometers.
- the expected conditions of use expose the hydrogel to moisture from a variety of sources, such as water present on a user's hand from washing, moisture secreted by mammalian sweat glands, and so forth.
- human sweat glands are of two types, eccrine and apocrine.
- the apocrine glands occur only in the armpits and about the ears, nipples, navel, and anogenital region, are scent glands.
- Eccrine glands are present throughout the body, including the hands, and are designed to regulate the temperature of the body. Obviously, the amount of fluid secreted by the eccrine glands depends on body temperature; however, even on cold days, some transepidermal water loss will likely occur.
- elastomeric gloves e.g., surgical gloves
- the temperature of the user's hand is likely to increase when wearing the glove. This temperature increase may also cause additional fluid to be secreted by the eccrine glands.
- the hydrogel when placed adjacent to a user's skin, the hydrogel will invariably be exposed to fluids secreted by eccrine glands or from some other source. This exposure leads to an increase degree of hydration for the hydrogel and a corresponding increase in the size of the hydrogel pores.
- the active agent within the crosslinked hydrogel network may be released. Once released, the active agent may interact directly with epithelial tissue at the cellular level to provide a benefit to the skin. Alternatively, the active agent may interact with components at or near the skin surface to provide the desired benefit.
- the active agent may be incorporated into the hydrogel before, during, and/or after its formation.
- the active agent may be mixed with the hydrogel-forming polymer and crosslinking agent prior to crosslinking. When crosslinked, the active agent is retained within the three-dimensional network.
- the active agent may also be applied after formation of the hydrogel.
- the hydrogel may be applied with an aqueous solution containing the active agent. As described above, the aqueous solution hydrates the hydrogel and causes an increase in porosity. Due to this increased porosity, the active agent may diffuse through the pores and into the crosslinked hydrogel network. The hydrogel is subsequently dried to retain the active agent therein.
- the size of the active agent is smaller than the pore size of the hydrogel when dry so that it remains physically retained within the hydrogel network.
- the active agent may also be chemically bonded to the hydrogel, such as through covalent, ionic, or hydrogen bonding.
- the “active agent” may be any compound or mixture thereof that may produce a desired result. Whether in solid or liquid form, the active agent typically possesses a sufficient solubility or miscibility in an aqueous system to render it capable of being released through the pores of the hydrogel network. Examples of such active agents include, but are not limited to, drugs, skin-conditioners, botanical agents, etc. “Drugs” include any physiologically or pharmacologically active substance that produces a localized or a systemic effect in animals. The drugs that may be delivered include, but are not limited to, anti-inflammatory agents, immunosuppressives, antimicrobials, anesthetics, analgesics, hormones, antihistamines, and so forth.
- glucocorticoids as anti-inflammatory agents, such as glucocorticoids (adrenocorticoid steroids).
- glucocorticoids include, for example, hydrocortisone, prenisone (deltasone) and predrisonlone (hydeltasol).
- Glucocorticoids may be used to treat inflammatory skin diseases, such as eczema (e.g., atopic dermatitis, contact dermatitis, and allergic dermatitis), bullous disease, collagen vascular diseases, sarcoidosis, Sweet's disease, pyoderma gangrenosum, Type I reactive leprosy, capillary hemangiomas, lichen planus, exfoliative dermatitis, erythema nodosum, hormonal abnormalities (including acne and hirsutism), toxic epidermal necrolysis, erythema multiforme, cutaneous T-cell lymphoma, discoid lupus erythematosus, and so forth.
- eczema e.g., atopic dermatitis, contact dermatitis, and allergic dermatitis
- bullous disease collagen vascular diseases
- sarcoidosis e.g., Sweet's disease
- Retinoids such as retinol, tretinoin, isotretinoin, etretinate, acitretin, and arotinoid
- Conditions that are possibly treatable using retinoids include, but are not limited to, acne, keratinization disorders, psoriasis, cutaneous aging, discoid lupus erythematosus, scleromyxedema, verrucous epidermal nevus, subcorneal pustular dermatosis, Reiter's syndrome, warts, lichen planus, acanthosis nigricans, sarcoidosis, Grover's disease, porokeratosis, and so forth.
- COX-2 inhibitors such as celecoxib, meloxicam, rofecoxib, and flosulide. These drugs inhibit the production of the COX-2 (cyclooxygenase-2) enzyme induced by pro-inflammatory stimuli in migratory cells and inflamed tissue.
- COX-2 cyclooxygenase-2
- NSAIDs nonsteroidal anti-inflammatory drugs
- examples of NSAIDs include, but are not limited to, Aspirin, Ibuprofen, Indomethacin, Phenylbutazone, Bromfenac, Sulindac, Nabumetone, Ketorolac, Mefenamic Acid, and Naproxen.
- Immunosuppressive drugs constitute an additional class of drugs from which the active agent may be selected. These drugs may be used to treat hyperproliferative diseases, such as psoriasis, as well as immune diseases, such as bullous dermatoses and leukocytoclastic vasculitis.
- drugs include, but are not limited to, antimetabolites, such as methotrexate, azathioprine, fluorouracil, hydroxyurea, 6-thioquanine, mycophenolate, chlorambucil, vinicristine, vinblasrine and dactinomycin; alkylating agents, such as cyclophosphamide, mechloroethamine hydrochloride, carmustine, taxol, tacrolimus and vinblastine; and so forth.
- antimetabolites such as methotrexate, azathioprine, fluorouracil, hydroxyurea, 6-thioquanine, mycophenolate, chlorambucil, vinicristine, vinblasrine and dactinomycin
- alkylating agents such as cyclophosphamide, mechloroethamine hydrochloride, carmustine, taxol, tacrolimus and vinblastine; and so forth.
- antimicrobial agents e.g., antibacterial, antifungal, antiviral, etc.
- Antibacterial agents are useful for treating conditions such as acne, cutaneous infections, and so forth.
- some suitable antimicrobial agents include, but are not limited to, bisphenols, such as 2,4,4′-trichloro-2′-hydroxydiphenyl ether (triclosan); quaternary ammonium compounds, such as benzalkonium chloride; esters of parahydroxy benzoic acid, such as methyl parabens; formaldehyde and formaldehyde donors, such as 2-bromo-2-nitro-1,3 propanediol, hydantoins, diazolidinyl urea, and imidazolidinyl urea; alkylisothizaolinones; phenoxyethanol; chlorhexidine gluconate; parachlorometaxylenol (PCMX); chitosan, such as chitosan pyrrolidone
- PCMX
- Antifungal agents may also be used to treat conditions, such as tinea corporis, tinea pedis, onychomycosis, candidiasis, tinea versicolor, onychomycosis, and so forth.
- antifungal agents include, but are not limited to, azole antifungals such as itraconazole, myconazole and fluconazole.
- antiviral agents include, but are not limited to, acyclovir, famciclovir, and valacyclovir. Such agents are useful for treating viral diseases, such as herpes.
- Antihistamines are still another class of suitable drugs.
- antihistamines include, for example, terfenadine, astemizole, lorotadine, cetirizine, acrivastine, temelastine, cimetidine, ranitidine, famotidine, nizatidine, and so forth.
- These agents may be used to treat conditions such as pruritus, atopic dermatitis, contact dermatitis, psoriasis, etc.
- local anesthetics constitute another class of drugs that may be used.
- Examples of such local anesthetics include, but are not limited to, lidocaine, bupibacaine, novocaine, procaine, tetracaine, benzocaine, mepivacaine, etidocaine, 2-chloroprocaine hydrochloride, and so forth.
- the active agent may be a skin-conditioner that improves moisture retention, softness, texture, and other properties of the skin.
- a skin-conditioner is an emollient that helps restore dry skin to a more normal moisture balance.
- emollients act on the skin by supplying fats and oils that blend with skin, making it pliable, repairing some of the cracks and fissures in the stratum corneum, and forming a protective film that traps water in the skin.
- Emollients that may be suitable for use in the present invention include, but are not limited to, beeswax, butyl stearate, cermides, cetyl palmitate, eucerit, isohexadecane, isopropyl palmitate, isopropyl myristate, mink oil, mineral oil, nut oil, oleyl alcohol, petroleum jelly or petrolatum, glyceral stearate, avocado oil, jojoba oil, lanolin (or woolwax), lanolin derivatives such as lanolin alcohol, retinyl palmitate (a vitamin A derivative), cetearyl alcohol, squalane, squalene, stearic acid, stearyl alcohol, myristal myristate, various lipids, decyl oleate and castor oil.
- humectant which may supply the skin with water by attracting moisture from the air and holding it on the skin.
- Humectants that may be suitable in the present invention include, but are not limited to, alanine, glycerin, polyethylene glycol, propylene glycol, butylene glycol, hyaluronic acid, Natural Moisturizing Factor (a mixture of amino acids and salts that are among the skin's natural humectants), saccharide isomerate, sodium lactate, sorbitol, urea, and so forth.
- Still other suitable skin-conditioners include antioxidants, a group of substances that prevent or slow the oxidation process of skin, thereby protecting it from premature aging.
- antioxidants include, but are not limited to, Vitamin E, Vitamin E derivatives, Vitamin C, Vitamin C derivatives, Vitamin A palmitate, butylated hydroxy toluene, phenols, phenolic derivatives, thiodipropionate esters, hydroquinone derivatives, alkylated aryl amine, combinations thereof, and so forth.
- the active agent may also be a botanical agent that may potentially reduce swelling, itching, reddening, etc.
- botanicals that may be used include, but are not limited to, Agnus castus, aloe vera, comfrey, calendula, dong quai, black cohosh, chamomile, evening primrose, Hypericum perforatum , licorice root, black currant seed oil, St.
- tea extracts lemon balm, capsicum, rosemary, Areca catechu , mung bean, borage seed oil, witch hazel, fenugreek, lavender, soy, almonds, chamomile extracts (e.g., bisabolol), elder flowers, honey, safflower oil, and elastin.
- the coating 26 may be formed using any suitable method. For example, techniques, such as dipping, spraying, patting, tumbling, etc., may be utilized in the present invention. Although it is normally desired that the coating 26 cover the entire surface 28 , it may also cover only a portion of the surface 28 .
- the average thickness of the coating 26 when dry, may range from about 0.05 to about 50 micrometers, in some embodiments from about 0.1 to about 20 micrometers, and in some embodiments, from about 1 to about 10 micrometers.
- the dried coating may comprise from about 0.0001 to about 1 gram per gram of the glove, in some embodiments from about 0.001 to about 0.5 grams per gram of the glove, and in some embodiments, from about 0.01 to about 0.2 grams per gram of the glove 20 .
- an additional coating may also cover an outer surface 30 (e.g., gripping surface) of the substrate body 24 that is the same or different than the coating 26 .
- the hydrogel coating 26 may controllably release an active agent that imparts certain benefits to a person with whom the glove 20 contacts.
- An elastomeric article made in accordance with the present invention may generally be formed using a variety of processes known in the art.
- any process capable of making an elastomeric article may be utilized in the present invention.
- elastomeric article formation techniques may employ dipping, spraying, halogenation, drying, curing, as well as any other technique known in the art.
- one embodiment of a method of dip-forming a natural rubber latex glove will now be described in more detail. Although a batch process is described herein, it should be understood that semi-batch and continuous processes may also be utilized in the present invention.
- any well-known former such as formers made from metals, ceramics, or plastics.
- the former is dried to remove water residue by conveying it through a preheated oven.
- the preheated former is then dipped into a bath containing a coagulant, a surfactant, water, and optionally other ingredients, such as a powder.
- the coagulant may contain calcium ions (e.g., calcium nitrate) to break the protection system of the emulsion, thereby allowing the latex to deposit on the former.
- the powder may be calcium carbonate powder, which later acts as a release agent.
- the surfactant provides good wetting to avoid forming a meniscus and trapping air between the form and deposited latex, particularly in the cuff area.
- the former has been preheated in the drying step and the residual heat dries off the water leaving, for example, calcium nitrate, calcium carbonate powder, and surfactant on the surface of the former.
- suitable coagulant solutions are also described in U.S. Pat. No. 4,310,928 to Joung, which is incorporated herein in its entirety by reference thereto for all purposes.
- the coated former is then dipped into a tank containing a natural rubber latex bath.
- the bath contains, for example, natural rubber latex, stabilizers, antioxidants, curing activators, organic accelerators, vulcanizers, and so forth.
- the stabilizers may, for example, be phosphate-type surfactants.
- the antioxidants may be phenol-based compounds, such as 2,2′-methylenebis (4-methyl-6-t-butylphenol).
- the curing activator may be zinc oxide.
- the organic accelerator may be dithiocarbamate.
- the vulcanizer may be sulfur or a sulfur-containing compound. If these materials are used, the stabilizer, antioxidant, activator, accelerator and vulcanizer may be dispersed into water to avoid crumb formation by using a ball mill.
- the substrate body 24 may have a thickness of from about 0.1 to about 0.3 millimeters.
- a bead roll station may, in some embodiments, be utilized to impart a cuff to the glove 20 .
- the bead roll station may contain one or more bead rolls such that the former is indexed therethrough to be provided with cuffs.
- the latex-coated former is then dipped into a leaching tank in which hot water is circulated to remove the water-soluble components, such as residual calcium nitrates and proteins contained in the natural latex. This leaching process may continue for about twelve minutes with the tank water being about 49° C.
- the latex-coated former may then be dipped into a solution to form the hydrogel coating 26 of the glove 20 .
- the latex-coated former is dipped into an aqueous solution of a water-soluble hydrogel-forming polymer or a mixture of such polymers.
- the aqueous composition may, for instance, include from about 0.1 wt. % to about 30 wt. % of hydrogel-forming polymer(s), in some embodiments from about 0.5 wt. % to about 10 wt. % of hydrogel-forming polymer(s), and in some embodiments, from about 1 wt. % to about 5 wt. % of hydrogel-forming polymer(s).
- the amount of active agent employed may vary depending on the type of active agent, the type of hydrogel, etc. Specifically, hydrogels that provide a slow release rate may require a higher active agent content than hydrogels that provide a fast release rate.
- the aqueous solution may contain from about 0.0001 wt. % to about 30 wt. % of active agent(s), in some embodiments from about 0.001 wt. % to about 10 wt. % active agent(s), and in some embodiments, from about 0.1 wt. % to about 5 wt. % active agent(s).
- the aqueous solution may also contain other components.
- the aqueous solution may contain from about 0.01 wt. % to about 10 wt. % crosslinking agent(s), in some embodiments from about 0.1 wt. % to about 5 wt. % crosslinking agent(s), and in some embodiments, from about 0.2 wt. % to about 2 wt. % crosslinking agent(s).
- Water typically constitutes from about 70 wt. % to about 99.9 wt. %, and in some embodiments, from about 90 wt. % to about 99 wt. % of the aqueous solution. Additional dips may be utilized to build up the desired thickness of the coating 26 . Further, the coating 26 may alternatively be applied to the former before it is dipped into the latex-containing bath(s).
- a catalyst such as p-toluene sulfonic acid or hydrochloric acid
- polymerization initiators may also be utilized, such as described in U.S. Pat. No. 6,242,042 to Goldstein, et al., which is incorporated herein in its entirety by reference thereto for all purposes.
- a pH adjuster such as an acid or base, may be also be added to achieve a certain pH.
- the former is sent to a curing station (e.g., oven) where the natural rubber is vulcanized and the hydrogel-forming polymer is crosslinked.
- the curing station may initially evaporate any remaining water and then proceed to the higher temperature vulcanization and crosslinking steps.
- curing of the hydrogel-forming polymer may be initiated by heating at a temperature from about 25° C. to about 200° C., in some embodiments from about 50° C. to about 150° C., and in some embodiments from about 70° C. to about 120° C., for a period of time of from about 1 minute to about 12 hours, in some embodiments from about 5 minutes to about 5 hours, and in some embodiments, from about 10 minutes to about 1 hour.
- Vulcanization may occur at the same time as the crosslinking of the hydrogel-forming polymer, or at a different time.
- the oven may be divided into four different zones with a former being conveyed through the zones of increasing temperature.
- One example is an oven having four zones with the first two zones being dedicated to drying, and the second two zones being primarily to vulcanization and crosslinking of the hydrogel polymer.
- Each of the zones may have a slightly higher temperature, for example, the first zone at about 80° C., the second zone at about 95° C., a third zone at about 105° C., and a final zone at about 115° C.
- the residence time of the former within a zone may, for instance, be about 10 minutes.
- the former may then be transferred to a stripping station.
- the stripping station may involve automatic or manual removal of the glove 20 from the former.
- the glove 20 is manually removed from the former by turning it inside out as it is stripped from the former.
- the glove 20 may be rinsed in water and dried.
- a coating may be applied to enhance the gripping properties of the glove 20 .
- a silicone emulsion e.g., DC 365, available from Dow Corning
- a high shear mixer to achieve a homogeneous solution having the desired solids content.
- the resulting emulsion may then be applied to the surface 30 of the substrate body 24 in a variety of different ways.
- the glove 20 is immersed in a tumbler for a certain period of time (e.g.,1 -10 minutes) during which the grip surface 30 is rinsed with the silicone emulsion.
- the grip surface 30 may be sprayed with the silicone emulsion using a conventional spray nozzle.
- the glove 20 is then dried.
- the glove 20 may be dried at a temperature of from about 20° C. to about 200° C., and in some embodiments, from about 35° C. to about 115° C.
- Halogenation e.g., chlorination
- halogenation may be performed in any suitable manner known to those skilled in the art. Such methods include (1) direct injection of chlorine gas into a water mixture, (2) mixing high-density bleaching powder and aluminum chloride in water, (3) brine electrolysis to produce chlorinated water, and (4) acidified bleach. Examples of such methods are described in U.S. Pat. Nos.
- chlorine gas is injected into a water stream and then fed into a chlorinator (a closed vessel) containing the glove.
- the concentration of chlorine may be monitored and controlled to control the degree of chlorination.
- the chlorine concentration is typically at least about 100 parts per million (ppm), in some embodiments from about 200 ppm to about 3500 ppm, and in some embodiments, from about 300 ppm to about 600 ppm, e.g., about 400 ppm.
- the time duration of the chlorination step may also be controlled to control the degree of chlorination and may range, for example, from about 1 to about 10 minutes, e.g., 4 minutes.
- the glove 20 may then be rinsed with tap water at about room temperature. This rinse cycle may be repeated as necessary. Once all water is removed, the glove 20 is tumbled to drain excess water.
- an additional lubricant may be applied over the hydrogel coating 26 so long as it does not adversely affect the ability of the active agent be controllably released.
- the lubricant may cover those portions of the surface 28 root covered by the coating 26 .
- Suitable lubricants include silicone emulsions, such as described in U.S. Patent Application Publication No. 2003/0118837 to Modha, et al., which is incorporated herein in its entirety by reference thereto for all purposes.
- a pre-heated, glove-shaped former was dipped into a coagulant solution that contained calcium nitrate, calcium carbonate, a surfactant, and water.
- the coated former was then dipped into a dip tank containing compounded, pre-vulcanized natural rubber latex. After dipping, the former was removed from the natural rubber latex dip tank and leached with water. Thereafter, the latex-coated former was cured in an oven at a temperature of 115° C. for about 20 minutes. The glove was manually removed from the former by turning the glove inside out as it was stripped from its corresponding former.
- the glove After being removed from the former, the glove was also rinsed in deionized water. The thickness of the resulting glove was 0.24 millimeters. After the drying process, the glove was turned inside out and placed into a chlorinator. Chlorine gas mixed with a water stream was injected into the chlorinator to chlorinate the donning surface of the glove. The chlorine concentration was 875 ppm and the pH was 1.8. The glove was immersed in the chlorine solution for 4 minutes. After chlorination, the glove was inverted and dried at a temperature of about 55° C. for 40 minutes.
- the latex glove was then dipped into a solution containing 96.725 wt. % water, 0.25 wt. % melamine-formaldehyde (crosslinking agent), 0.025 wt % of p-toluene sulfonic acid (a catalyst), and 3 wt. % of a hydrogel-forming polymer formed from hydroxy ethyl acrylate and acrylic acid monomers, which was obtained from Ortec, Inc. of Easley, S.C.
- the mixture was then heated to a temperature of about 120° C. for about 18 minutes to crosslink the polymer and form a hydrogel coating on the glove.
- the hydrogel-coated glove To test the ability of the hydrogel-coated glove to controllably release an active agent, it was immersed for 7 hours in an aqueous solution containing 99.5 wt. % water and 0.5 wt. % of a dye (Fiber Identification Stain #7, available from Dupont). A comparative glove was also immersed for 7 hours in the same aqueous solution. The comparative glove was identical to the test glove, except that it did not contain a hydrogel coating. Each glove was removed from the dye solution and rinsed several times with water to remove excess dye. The gloves were then dried overnight in an oven at 60° C. Thereafter, 50 milliliters of water was injected into the hand-receiving cavity formed by each glove and allowed to remain for 2 minutes.
- a dye Fiber Identification Stain #7
- the water was poured out, and an additional 50 milliliters of water was injected into the glove and allowed to remain for 3 minutes. This process was repeated with water being injected into the glove and allowed to remain for varying periods of time up to 280 minutes of contact time.
- the absorbance values of the water samples were then measured at a wavelength of 547 nanometers with a UV-visible spectrophotometer, which is commercially available from Shimadzu of Kyoto, Japan (Model No. UV-1601). The absorbance correlated with the amount of dye that had diffused out of the glove and into the water.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Dispersion Chemistry (AREA)
- Gloves (AREA)
- Laminated Bodies (AREA)
- Cosmetics (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Coating Of Shaped Articles Made Of Macromolecular Substances (AREA)
Abstract
An elastomeric glove that contains a hydrogel coating is provided. The present inventors have discovered that the hydrogel coating is capable of improving donning (damp and/or dry) and also imparting certain other benefits to a wearer of the glove. Specifically, the hydrogel coating includes an active agent that is retained within a crosslinked hydrogel network. When the hydrogel coating is exposed to an aqueous environment, it swells, allowing the active agent to diffuse through pores and contact the skin of a wearer.
Description
- Elastomeric gloves are formed to fit tightly against a user's hand and provide good gripping and tactile characteristics during use. In addition, elastomeric gloves are normally liquid-impermeable to provide a barrier between the wearer and the environment in which the gloves are used. Unfortunately, these desired characteristics of elastomeric gloves create a harsh environment for the wearer's skin. For example, perspiration is a common problem for glove wearers, and the resulting moist environment may lead to various skin problems, including, for example, growth of fungi and yeast, as well as bacterial and viral infections of the skin. In addition, those who utilize elastomeric gloves in the medical field frequently clean their hands with soap or sanitary alcohol formulations. This constant cleaning is harsh on the skin, causing excessive skin dryness that may exacerbate other skin problems.
- In the past, the wearer-contacting surface of elastomeric gloves was treated with a powder, such as talc or calcium carbonate powder, to absorb moisture and alleviate some of the problems faced by wearers of the glove. The powder also facilitated donning. However, while powders may still be acceptable in certain applications, they are typically undesired in surgical or cleanroom-type environments. As such, a need currently exists for an improved glove that is capable of relieving some of the problems that might stem from the harsh environment to which the wearer's hand is exposed during use.
- In accordance with one embodiment of the present invention, an elastomeric glove is disclosed that comprises a substrate body including a layer made of an elastomeric material. The substrate body defines an inner surface and an outer surface. A coating overlies the inner surface of the substrate body and defines a user-contacting surface of the glove. The coating comprises a crosslinked hydrogel network within which is retained an active agent capable of imparting a benefit to a user. The active agent is releasable from the network when the coating is contacted with an aqueous environment.
- In accordance with another embodiment of the present invention, an elastomeric article is disclosed that comprises a substrate body including a layer made of an elastomeric material. The elastomeric material is selected from the group consisting of styrene-ethylene-butylene-styrene block copolymers, styrene-isoprene-styrene block copolymers, styrene-butadiene-styrene block copolymers, styrene-isoprene block copolymers, styrene-butadiene block copolymers, natural rubber latex, nitrile rubbers, isoprene rubbers, chloroprene rubbers, polyvinyl chlorides, silicone rubbers, and combinations thereof. The substrate body defines a surface over which lies a coating. The coating comprises a substantially water-insoluble, crosslinked hydrogel network within which is retained an active agent capable of imparting a benefit. The active agent is releasable from the network when the coating is contacted with water.
- In accordance with still another embodiment of the present invention, a method for forming an elastomeric glove containing a substrate body and a coating overlying a surface of the substrate body is disclosed. The method comprises dipping a hand-shaped former into at least one bath containing an elastomeric polymer to form the substrate body of the glove. An aqueous solution is applied to the substrate body or the hand-shaped former to form the coating of the glove. The aqueous solution contains at least one hydrogel-forming polymer and an active agent. The hydrogel-forming polymer is crosslinked to form a hydrogel network, wherein the active agent is retained within the hydrogel network and is releasable therefrom when the coating is contacted with an aqueous environment.
- In accordance with yet another embodiment of the present invention, a method for forming an elastomeric glove containing a substrate body and a coating overlying a surface of the substrate body is disclosed. The method comprises dipping a hand-shaped former into at least one bath containing an elastomeric polymer to form the substrate body of the glove. An aqueous solution is applied to the substrate body or the hand-shaped former to form the coating of the glove. The aqueous solution contains at least one hydrogel-forming polymer. The hydrogel-forming polymer is crosslinked to form a hydrogel network. An active agent is incorporated into the hydrogel network, the active agent being releasable therefrom when the coating is contacted with an aqueous environment.
- Other features and aspects of the present invention are discussed in greater detail below.
- A full and enabling disclosure of the present invention, including the best mode thereof, directed to one of ordinary skill in the art, is set forth more particularly in the remainder of the specification, which makes reference to the appended figures in which:
-
FIG. 1 is a perspective view of one embodiment of an elastomeric glove made according to the invention; -
FIG. 2 is a cross-sectional view of the glove illustrated inFIG. 1 taken along a line 2-2; and -
FIG. 3 is a graphic illustration of the results obtained in the Example, in which the absorbance of the dye is shown for various diffusion times. - Repeat use of reference characters in the present specification and drawings is intended to represent same or analogous features or elements of the invention.
- Reference now will be made in detail to various embodiments of the invention, one or more examples of which are set forth below. Each example is provided by way of explanation of the invention, not limitation of the invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment, may be used on another embodiment to yield a still further embodiment. Thus, it is intended that the present invention covers such modifications and variations as come within the scope of the appended claims and their equivalents.
- In general, the present invention is directed to an elastomeric article, such as a condom or glove, which contains a hydrogel coating. The present inventors have discovered that the hydrogel coating is capable of improving donning (damp and/or dry) and also imparting certain other benefits to a user of the article. Specifically, the hydrogel coating includes an active agent that is retained within a crosslinked hydrogel network. When the hydrogel coating is exposed to an aqueous environment, it swells, allowing the active agent to diffuse through pores and contact the skin of a user.
- Referring to
FIGS. 1-2 , for example, one embodiment of anelastomeric glove 20 is illustrated that may be placed over the hand of auser 22. Theglove 20 includes asubstrate body 24 having the basic shape of the glove. Thesubstrate body 24 may generally be formed from any of a variety of natural and/or synthetic elastomeric materials known in the art. For instance, some examples of suitable elastomeric materials include, but are not limited to, S-EB-S (styrene-ethylene-butylene-styrene) block copolymers, S-B-S (styrene-isoprene-styrene) block copolymers, S-B-S (styrene-butadiene-styrene) block copolymers, S-I (styrene-isoprene) block copolymers, S-B (styrene-butadiene) block copolymers, natural rubber latex, nitrile rubbers, isoprene rubbers, chloroprene rubbers, polyvinyl chlorides, silicone rubbers, and combinations thereof. Other suitable elastomeric materials that may be used to form thesubstrate body 24 may be described in U.S. Pat. Nos. 5,112,900 to Buddenhagen, et al.; 5,407,715 to Buddenhagen, et al.; 5,900,452 to Plamthottam; 6,288,159 to Plamthottam; and 6,306,514 to Weikel, et al., which are incorporated herein in their entirety by reference thereto for all purposes. - In one embodiment, the
substrate body 24 is formed from natural rubber latex. To form thesubstrate body 24 from natural latex, a former is initially dipped into a coagulant bath that facilitates later stripping of the glove from the former. The coagulant bath may include calcium carbonate and/or calcium nitrate. Thereafter, the coagulant-coated former is dried and subsequently dipped into one or more latex baths. The resulting latex layer(s) are then typically leached in water to extract a large percentage of the water-soluble impurities in the latex and coagulant. The coated former is then dried to cure (i.e., crosslink) the rubber. It should be understood that the conditions, process, and materials used in forming natural rubber gloves are well known in the art, and are not critical to the practice of the present invention. - Regardless of the particular material used to form the
substrate body 24, theglove 20 also includes acoating 26 that is present on aninner surface 28 defined by thesubstrate body 24. In this embodiment, thecoating 26 defines a wearer-contactingsurface 27 of theglove 20 that contacts the body of theuser 22. Thecoating 26 serves dual purposes in the present invention. Specifically, thecoating 26 has a low coefficient of friction that facilitates donning of theglove 20 when the user's hand is either dry or wet, i.e., dry and damp donning. The low coefficient of friction may be imparted through surface texture and/or through the lubricity of the materials used to form thecoating 26. In addition to facilitating donning, another purpose of thecoating 26 is to controllably release an active agent contained therein for contacting a user's skin and providing some desired benefit. The present inventors have discovered that such dual purposes may be accomplished by forming thecoating 26 from a hydrogel within which is retained the active agent. - Generally speaking, any of a variety of polymers may be utilized in the present invention to form the hydrogel. Typically, the polymer is utilized that is formed from at least one hydrogel-forming monomer that is hydrophilic and water-soluble. There are many known hydrophilic, water-soluble monomers that may be used in the present invention to form the hydrogel polymer. Some examples of such monomers include, but are not limited to, vinyl pyrrolidone, hydroxyethyl acrylate or methacrylate (e.g., 2-hydroxyethyl methacrylate), hydroxypropyl acrylate or methacrylate, acrylic or methacrylic acid, acrylic or methacrylic esters or vinyl pyridine, acrylamide, vinyl alcohol, ethylene oxide, derivatives thereof, and so forth. Other examples of suitable monomers are described in U.S. Pat. No. 4,499,154 to James, et al., which is incorporated herein in its entirety by reference thereto for all purposes. The resulting polymers may be homopolymers or interpolymers (e.g., copolymer, terpolymer, etc.), and may be nonionic, anionic, cationic, or amphoteric. In addition, the polymer may be of one type (i.e., homogeneous), or mixtures of different polymers may be used (i.e., heterogeneous).
- To form the hydrogel, the polymer(s) are crosslinked using any known crosslinking technique, including known ionic or covalent crosslinking techniques. For example, in some embodiments, a crosslinking agent may be utilized to facilitate crosslinking. Examples of crosslinking agents include, but are not limited to, polyhydric alcohols (e.g., glycerol); polyaziridine compounds (e.g., 2,2-bishydroxymethyl butanoltris[3-(1 -aziridine) propionate] or triaziridine); epoxy compounds; haloepoxy compounds (e.g., epicholorhydrin); aldehyde compounds (e.g., urea-formaldehyde, melamine-formaldehyde, hydantoin-formaldehyde, glutaraldehyde, glyoxal, malonaldehyde, succinaldehyde, adipaldehyde, or dialdehyde starch); polyisocyanate compounds (e.g., 2,4-toluene diisocyanate); etc. Crosslinking may be carried out before, during, and/or after application of the polymer to the
surface 28 of thesubstrate body 24. For example, in one embodiment, an aqueous solution containing a crosslinking agent and polymer is applied to thesurface 28. Thereafter, the mixture is cured at elevated temperatures. Besides thermal activation, crosslinking may also be carried out using other well-known techniques. For example, crosslinking may be induced with ionizing radiation, which is radiation having an energy sufficient to either directly or indirectly produce ions in a medium. Some suitable examples of ionizing radiation that may be used in the present invention include, but are not limited to, electron beam radiation, natural and artificial radio isotopes (e.g., α, β, and γ rays), x-rays, neutron beams, positively charged beams, laser beams, and so forth. Electron beam radiation, for instance, involves the production of accelerated electrons by an electron beam device. Electron beam devices are generally well known in the art. For instance, in one embodiment, an electron beam device may be used that is available from Energy Sciences, Inc., of Woburn, Mass. under the name “Microbeam LV.” Other examples of suitable electron beam devices are described in U.S. Pat. Nos. 5,003,178 to Livesay; 5,962,995 to Avnery; 6,407,492 to Avnery, et al., which are incorporated herein in their entirety by reference thereto for all purposes. - Regardless of the technique utilized, crosslinking forms a hydrogel constituted by a three-dimensional network that is substantially water-insoluble. Thus, when exposed to water, the hydrogel does not dissolve, but instead may absorb a certain amount of water. For example, the hydrogel is capable of achieving a water content of from about 20% to about 90%, in some embodiments from about 35% to about 85%, and in some embodiments, from about 50% to about 80%. The water content of the hydrogel is determined as follows:
Upon absorbing water, the hydrogel swells, thereby increasing the area between crosslinks to form pores. For example, at its highest water content, the hydrogel may possess pores having an average size of from about 1 nanometer to about 10 microns, in some embodiments from about 10 nanometers to about 1 micron, and in some embodiments, from about 50 nanometers to about 100 nanometers. - When present on the
glove 20, the expected conditions of use expose the hydrogel to moisture from a variety of sources, such as water present on a user's hand from washing, moisture secreted by mammalian sweat glands, and so forth. For instance, human sweat glands are of two types, eccrine and apocrine. The apocrine glands occur only in the armpits and about the ears, nipples, navel, and anogenital region, are scent glands. Eccrine glands, however, are present throughout the body, including the hands, and are designed to regulate the temperature of the body. Obviously, the amount of fluid secreted by the eccrine glands depends on body temperature; however, even on cold days, some transepidermal water loss will likely occur. Because elastomeric gloves (e.g., surgical gloves) often fit tightly over a user's hand and do not allow outside air to readily cool the skin, the temperature of the user's hand is likely to increase when wearing the glove. This temperature increase may also cause additional fluid to be secreted by the eccrine glands. - Thus, when placed adjacent to a user's skin, the hydrogel will invariably be exposed to fluids secreted by eccrine glands or from some other source. This exposure leads to an increase degree of hydration for the hydrogel and a corresponding increase in the size of the hydrogel pores. As the pore size increases, the active agent within the crosslinked hydrogel network may be released. Once released, the active agent may interact directly with epithelial tissue at the cellular level to provide a benefit to the skin. Alternatively, the active agent may interact with components at or near the skin surface to provide the desired benefit.
- The active agent may be incorporated into the hydrogel before, during, and/or after its formation. In one embodiment, for example, the active agent may be mixed with the hydrogel-forming polymer and crosslinking agent prior to crosslinking. When crosslinked, the active agent is retained within the three-dimensional network. As stated, the active agent may also be applied after formation of the hydrogel. For example, the hydrogel may be applied with an aqueous solution containing the active agent. As described above, the aqueous solution hydrates the hydrogel and causes an increase in porosity. Due to this increased porosity, the active agent may diffuse through the pores and into the crosslinked hydrogel network. The hydrogel is subsequently dried to retain the active agent therein. Typically, the size of the active agent is smaller than the pore size of the hydrogel when dry so that it remains physically retained within the hydrogel network. Apart from being physically retained within the hydrogel, the active agent may also be chemically bonded to the hydrogel, such as through covalent, ionic, or hydrogen bonding.
- Generally speaking, the “active agent” may be any compound or mixture thereof that may produce a desired result. Whether in solid or liquid form, the active agent typically possesses a sufficient solubility or miscibility in an aqueous system to render it capable of being released through the pores of the hydrogel network. Examples of such active agents include, but are not limited to, drugs, skin-conditioners, botanical agents, etc. “Drugs” include any physiologically or pharmacologically active substance that produces a localized or a systemic effect in animals. The drugs that may be delivered include, but are not limited to, anti-inflammatory agents, immunosuppressives, antimicrobials, anesthetics, analgesics, hormones, antihistamines, and so forth. Numerous such compounds are known to those of skill in the art and described, for example, in The Pharmacological Basis of Therapeutics, Hardman, Limbird, Goodman & Gilman, McGraw-Hill, New York, (1996), as well as U.S. Pat. Nos. 6,419,913 to Niemiec, et al.; 6,562,363 to Mantelle. et al.; 6,593,292 to Rothbard, et al.; 6,567,693 to Allen, Jr.; and 6,645,181 to Lavi, et al., all of which are incorporated herein in their entirety by reference thereto for all purposes. Although several examples of active agents are described herein, it should be understood that the present invention is by no means limited to any particular active agent. In fact, any active agent having any benefit whatsoever to a user may be utilized in accordance with the present invention.
- In this regard, one class of suitable drugs includes anti-inflammatory agents, such as glucocorticoids (adrenocorticoid steroids). Exemplary glucocorticoids include, for example, hydrocortisone, prenisone (deltasone) and predrisonlone (hydeltasol). Glucocorticoids may be used to treat inflammatory skin diseases, such as eczema (e.g., atopic dermatitis, contact dermatitis, and allergic dermatitis), bullous disease, collagen vascular diseases, sarcoidosis, Sweet's disease, pyoderma gangrenosum, Type I reactive leprosy, capillary hemangiomas, lichen planus, exfoliative dermatitis, erythema nodosum, hormonal abnormalities (including acne and hirsutism), toxic epidermal necrolysis, erythema multiforme, cutaneous T-cell lymphoma, discoid lupus erythematosus, and so forth. Retinoids, such as retinol, tretinoin, isotretinoin, etretinate, acitretin, and arotinoid, may also be used. Conditions that are possibly treatable using retinoids include, but are not limited to, acne, keratinization disorders, psoriasis, cutaneous aging, discoid lupus erythematosus, scleromyxedema, verrucous epidermal nevus, subcorneal pustular dermatosis, Reiter's syndrome, warts, lichen planus, acanthosis nigricans, sarcoidosis, Grover's disease, porokeratosis, and so forth. Other suitable anti-inflammatory drugs are COX-2 inhibitors, such as celecoxib, meloxicam, rofecoxib, and flosulide. These drugs inhibit the production of the COX-2 (cyclooxygenase-2) enzyme induced by pro-inflammatory stimuli in migratory cells and inflamed tissue. In addition, nonsteroidal anti-inflammatory drugs (NSAIDs) may also be utilized. Examples of NSAIDs include, but are not limited to, Aspirin, Ibuprofen, Indomethacin, Phenylbutazone, Bromfenac, Sulindac, Nabumetone, Ketorolac, Mefenamic Acid, and Naproxen.
- Immunosuppressive drugs constitute an additional class of drugs from which the active agent may be selected. These drugs may be used to treat hyperproliferative diseases, such as psoriasis, as well as immune diseases, such as bullous dermatoses and leukocytoclastic vasculitis. Examples of such drugs include, but are not limited to, antimetabolites, such as methotrexate, azathioprine, fluorouracil, hydroxyurea, 6-thioquanine, mycophenolate, chlorambucil, vinicristine, vinblasrine and dactinomycin; alkylating agents, such as cyclophosphamide, mechloroethamine hydrochloride, carmustine, taxol, tacrolimus and vinblastine; and so forth.
- Another class of suitable drugs includes antimicrobial agents, e.g., antibacterial, antifungal, antiviral, etc. Antibacterial agents are useful for treating conditions such as acne, cutaneous infections, and so forth. For instance, some suitable antimicrobial agents include, but are not limited to, bisphenols, such as 2,4,4′-trichloro-2′-hydroxydiphenyl ether (triclosan); quaternary ammonium compounds, such as benzalkonium chloride; esters of parahydroxy benzoic acid, such as methyl parabens; formaldehyde and formaldehyde donors, such as 2-bromo-2-nitro-1,3 propanediol, hydantoins, diazolidinyl urea, and imidazolidinyl urea; alkylisothizaolinones; phenoxyethanol; chlorhexidine gluconate; parachlorometaxylenol (PCMX); chitosan, such as chitosan pyrrolidone carboxylate; combinations thereof, and so forth. Antifungal agents may also be used to treat conditions, such as tinea corporis, tinea pedis, onychomycosis, candidiasis, tinea versicolor, onychomycosis, and so forth. Examples of antifungal agents include, but are not limited to, azole antifungals such as itraconazole, myconazole and fluconazole. Examples of antiviral agents include, but are not limited to, acyclovir, famciclovir, and valacyclovir. Such agents are useful for treating viral diseases, such as herpes.
- Antihistamines are still another class of suitable drugs. Examples of such antihistamines include, for example, terfenadine, astemizole, lorotadine, cetirizine, acrivastine, temelastine, cimetidine, ranitidine, famotidine, nizatidine, and so forth. These agents may be used to treat conditions such as pruritus, atopic dermatitis, contact dermatitis, psoriasis, etc. Further, local anesthetics constitute another class of drugs that may be used. Examples of such local anesthetics include, but are not limited to, lidocaine, bupibacaine, novocaine, procaine, tetracaine, benzocaine, mepivacaine, etidocaine, 2-chloroprocaine hydrochloride, and so forth.
- Other than drugs, various other active agents may be released from the glove according to the present invention. For instance, in some embodiments, the active agent may be a skin-conditioner that improves moisture retention, softness, texture, and other properties of the skin. One example of such a skin-conditioner is an emollient that helps restore dry skin to a more normal moisture balance. Specifically, emollients act on the skin by supplying fats and oils that blend with skin, making it pliable, repairing some of the cracks and fissures in the stratum corneum, and forming a protective film that traps water in the skin. Emollients that may be suitable for use in the present invention include, but are not limited to, beeswax, butyl stearate, cermides, cetyl palmitate, eucerit, isohexadecane, isopropyl palmitate, isopropyl myristate, mink oil, mineral oil, nut oil, oleyl alcohol, petroleum jelly or petrolatum, glyceral stearate, avocado oil, jojoba oil, lanolin (or woolwax), lanolin derivatives such as lanolin alcohol, retinyl palmitate (a vitamin A derivative), cetearyl alcohol, squalane, squalene, stearic acid, stearyl alcohol, myristal myristate, various lipids, decyl oleate and castor oil. Another possible skin conditioner is a humectant, which may supply the skin with water by attracting moisture from the air and holding it on the skin. Humectants that may be suitable in the present invention include, but are not limited to, alanine, glycerin, polyethylene glycol, propylene glycol, butylene glycol, hyaluronic acid, Natural Moisturizing Factor (a mixture of amino acids and salts that are among the skin's natural humectants), saccharide isomerate, sodium lactate, sorbitol, urea, and so forth. Still other suitable skin-conditioners include antioxidants, a group of substances that prevent or slow the oxidation process of skin, thereby protecting it from premature aging. Exemplary antioxidants include, but are not limited to, Vitamin E, Vitamin E derivatives, Vitamin C, Vitamin C derivatives, Vitamin A palmitate, butylated hydroxy toluene, phenols, phenolic derivatives, thiodipropionate esters, hydroquinone derivatives, alkylated aryl amine, combinations thereof, and so forth.
- The active agent may also be a botanical agent that may potentially reduce swelling, itching, reddening, etc. Examples of some botanicals that may be used include, but are not limited to, Agnus castus, aloe vera, comfrey, calendula, dong quai, black cohosh, chamomile, evening primrose, Hypericum perforatum, licorice root, black currant seed oil, St. John's wort, tea extracts, lemon balm, capsicum, rosemary, Areca catechu, mung bean, borage seed oil, witch hazel, fenugreek, lavender, soy, almonds, chamomile extracts (e.g., bisabolol), elder flowers, honey, safflower oil, and elastin.
- The
coating 26 may be formed using any suitable method. For example, techniques, such as dipping, spraying, patting, tumbling, etc., may be utilized in the present invention. Although it is normally desired that thecoating 26 cover theentire surface 28, it may also cover only a portion of thesurface 28. The average thickness of thecoating 26, when dry, may range from about 0.05 to about 50 micrometers, in some embodiments from about 0.1 to about 20 micrometers, and in some embodiments, from about 1 to about 10 micrometers. In addition, the dried coating may comprise from about 0.0001 to about 1 gram per gram of the glove, in some embodiments from about 0.001 to about 0.5 grams per gram of the glove, and in some embodiments, from about 0.01 to about 0.2 grams per gram of theglove 20. Further, besides covering thesurface 28, an additional coating may also cover an outer surface 30 (e.g., gripping surface) of thesubstrate body 24 that is the same or different than thecoating 26. For instance, when present on thesurface 30, thehydrogel coating 26 may controllably release an active agent that imparts certain benefits to a person with whom theglove 20 contacts. - An elastomeric article made in accordance with the present invention may generally be formed using a variety of processes known in the art. In fact, any process capable of making an elastomeric article may be utilized in the present invention. For example, elastomeric article formation techniques may employ dipping, spraying, halogenation, drying, curing, as well as any other technique known in the art. In this regard, one embodiment of a method of dip-forming a natural rubber latex glove will now be described in more detail. Although a batch process is described herein, it should be understood that semi-batch and continuous processes may also be utilized in the present invention.
- Initially, any well-known former, such as formers made from metals, ceramics, or plastics, is provided. The former is dried to remove water residue by conveying it through a preheated oven. The preheated former is then dipped into a bath containing a coagulant, a surfactant, water, and optionally other ingredients, such as a powder. The coagulant may contain calcium ions (e.g., calcium nitrate) to break the protection system of the emulsion, thereby allowing the latex to deposit on the former. The powder may be calcium carbonate powder, which later acts as a release agent. The surfactant provides good wetting to avoid forming a meniscus and trapping air between the form and deposited latex, particularly in the cuff area. As noted above, the former has been preheated in the drying step and the residual heat dries off the water leaving, for example, calcium nitrate, calcium carbonate powder, and surfactant on the surface of the former. Other suitable coagulant solutions are also described in U.S. Pat. No. 4,310,928 to Joung, which is incorporated herein in its entirety by reference thereto for all purposes.
- The coated former is then dipped into a tank containing a natural rubber latex bath. The bath contains, for example, natural rubber latex, stabilizers, antioxidants, curing activators, organic accelerators, vulcanizers, and so forth. The stabilizers may, for example, be phosphate-type surfactants. The antioxidants may be phenol-based compounds, such as 2,2′-methylenebis (4-methyl-6-t-butylphenol). The curing activator may be zinc oxide. The organic accelerator may be dithiocarbamate. The vulcanizer may be sulfur or a sulfur-containing compound. If these materials are used, the stabilizer, antioxidant, activator, accelerator and vulcanizer may be dispersed into water to avoid crumb formation by using a ball mill. This dispersion is then mixed into the latex. The former is dipped into one or more latex baths a sufficient number of times to build up the desired thickness on the former. By way of example, the
substrate body 24 may have a thickness of from about 0.1 to about 0.3 millimeters. - A bead roll station may, in some embodiments, be utilized to impart a cuff to the
glove 20. For instance, the bead roll station may contain one or more bead rolls such that the former is indexed therethrough to be provided with cuffs. The latex-coated former is then dipped into a leaching tank in which hot water is circulated to remove the water-soluble components, such as residual calcium nitrates and proteins contained in the natural latex. This leaching process may continue for about twelve minutes with the tank water being about 49° C. - The latex-coated former may then be dipped into a solution to form the
hydrogel coating 26 of theglove 20. In one embodiment, the latex-coated former is dipped into an aqueous solution of a water-soluble hydrogel-forming polymer or a mixture of such polymers. The aqueous composition may, for instance, include from about 0.1 wt. % to about 30 wt. % of hydrogel-forming polymer(s), in some embodiments from about 0.5 wt. % to about 10 wt. % of hydrogel-forming polymer(s), and in some embodiments, from about 1 wt. % to about 5 wt. % of hydrogel-forming polymer(s). The amount of active agent employed may vary depending on the type of active agent, the type of hydrogel, etc. Specifically, hydrogels that provide a slow release rate may require a higher active agent content than hydrogels that provide a fast release rate. In most embodiments, for example, the aqueous solution may contain from about 0.0001 wt. % to about 30 wt. % of active agent(s), in some embodiments from about 0.001 wt. % to about 10 wt. % active agent(s), and in some embodiments, from about 0.1 wt. % to about 5 wt. % active agent(s). The aqueous solution may also contain other components. For example, in some embodiments, the aqueous solution may contain from about 0.01 wt. % to about 10 wt. % crosslinking agent(s), in some embodiments from about 0.1 wt. % to about 5 wt. % crosslinking agent(s), and in some embodiments, from about 0.2 wt. % to about 2 wt. % crosslinking agent(s). Water typically constitutes from about 70 wt. % to about 99.9 wt. %, and in some embodiments, from about 90 wt. % to about 99 wt. % of the aqueous solution. Additional dips may be utilized to build up the desired thickness of thecoating 26. Further, thecoating 26 may alternatively be applied to the former before it is dipped into the latex-containing bath(s). - It should also be understood that other components may be present in the coating mixture. For example, to initiate or speed up the crosslinking process, a catalyst, such as p-toluene sulfonic acid or hydrochloric acid, may be utilized. In addition, polymerization initiators may also be utilized, such as described in U.S. Pat. No. 6,242,042 to Goldstein, et al., which is incorporated herein in its entirety by reference thereto for all purposes. A pH adjuster, such as an acid or base, may be also be added to achieve a certain pH.
- Once coated, the former is sent to a curing station (e.g., oven) where the natural rubber is vulcanized and the hydrogel-forming polymer is crosslinked. If desired, the curing station may initially evaporate any remaining water and then proceed to the higher temperature vulcanization and crosslinking steps. For instance, curing of the hydrogel-forming polymer may be initiated by heating at a temperature from about 25° C. to about 200° C., in some embodiments from about 50° C. to about 150° C., and in some embodiments from about 70° C. to about 120° C., for a period of time of from about 1 minute to about 12 hours, in some embodiments from about 5 minutes to about 5 hours, and in some embodiments, from about 10 minutes to about 1 hour. Vulcanization may occur at the same time as the crosslinking of the hydrogel-forming polymer, or at a different time. If desired, the oven may be divided into four different zones with a former being conveyed through the zones of increasing temperature. One example is an oven having four zones with the first two zones being dedicated to drying, and the second two zones being primarily to vulcanization and crosslinking of the hydrogel polymer. Each of the zones may have a slightly higher temperature, for example, the first zone at about 80° C., the second zone at about 95° C., a third zone at about 105° C., and a final zone at about 115° C. The residence time of the former within a zone may, for instance, be about 10 minutes.
- The former may then be transferred to a stripping station. The stripping station may involve automatic or manual removal of the
glove 20 from the former. For example, in one embodiment, theglove 20 is manually removed from the former by turning it inside out as it is stripped from the former. After being removed from the former, theglove 20 may be rinsed in water and dried. - Optionally, a coating may be applied to enhance the gripping properties of the
glove 20. For example, in one embodiment, a silicone emulsion (e.g., DC 365, available from Dow Corning) is first thoroughly mixed with water using a high shear mixer to achieve a homogeneous solution having the desired solids content. Thereafter, the resulting emulsion may then be applied to thesurface 30 of thesubstrate body 24 in a variety of different ways. For instance, in one embodiment, theglove 20 is immersed in a tumbler for a certain period of time (e.g.,1 -10 minutes) during which thegrip surface 30 is rinsed with the silicone emulsion. Alternatively, thegrip surface 30 may be sprayed with the silicone emulsion using a conventional spray nozzle. Once applied with the silicone emulsion, theglove 20 is then dried. For example, in some embodiments, theglove 20 may be dried at a temperature of from about 20° C. to about 200° C., and in some embodiments, from about 35° C. to about 115° C. - After the drying process, the glove is optionally inverted and halogenated. Halogenation (e.g., chlorination) may be performed in any suitable manner known to those skilled in the art. Such methods include (1) direct injection of chlorine gas into a water mixture, (2) mixing high-density bleaching powder and aluminum chloride in water, (3) brine electrolysis to produce chlorinated water, and (4) acidified bleach. Examples of such methods are described in U.S. Pat. Nos. 3,411,982 to Kavalir; 3,740,262 to Agostinelli; 3,992,221 to Homsy, et al.; 4,597,108 to Momose; and 4,851,266 to Momose, 5,792,531 to Littleton, et al., which are incorporated herein in their entirety by reference thereto for all purposes. In one embodiment, for example, chlorine gas is injected into a water stream and then fed into a chlorinator (a closed vessel) containing the glove. The concentration of chlorine may be monitored and controlled to control the degree of chlorination. The chlorine concentration is typically at least about 100 parts per million (ppm), in some embodiments from about 200 ppm to about 3500 ppm, and in some embodiments, from about 300 ppm to about 600 ppm, e.g., about 400 ppm. The time duration of the chlorination step may also be controlled to control the degree of chlorination and may range, for example, from about 1 to about 10 minutes, e.g., 4 minutes. Still within the chlorinator, the
glove 20 may then be rinsed with tap water at about room temperature. This rinse cycle may be repeated as necessary. Once all water is removed, theglove 20 is tumbled to drain excess water. - Although various constructions and techniques for forming elastomeric articles have been described above, it should be understood that the present invention is not limited to any particular construction or technique for forming the article. For example, the layers described above may not be utilized in all instances. Additionally, other layers not specifically referred to above may be utilized in the present invention. For example, in one embodiment, an additional lubricant may be applied over the
hydrogel coating 26 so long as it does not adversely affect the ability of the active agent be controllably released. Although not required, the lubricant may cover those portions of thesurface 28 root covered by thecoating 26. Suitable lubricants include silicone emulsions, such as described in U.S. Patent Application Publication No. 2003/0118837 to Modha, et al., which is incorporated herein in its entirety by reference thereto for all purposes. - The present invention may be better understood with reference to the following example.
- The ability to form an elastomeric glove in accordance with the present invention was demonstrated. Initially, a pre-heated, glove-shaped former was dipped into a coagulant solution that contained calcium nitrate, calcium carbonate, a surfactant, and water. The coated former was then dipped into a dip tank containing compounded, pre-vulcanized natural rubber latex. After dipping, the former was removed from the natural rubber latex dip tank and leached with water. Thereafter, the latex-coated former was cured in an oven at a temperature of 115° C. for about 20 minutes. The glove was manually removed from the former by turning the glove inside out as it was stripped from its corresponding former. After being removed from the former, the glove was also rinsed in deionized water. The thickness of the resulting glove was 0.24 millimeters. After the drying process, the glove was turned inside out and placed into a chlorinator. Chlorine gas mixed with a water stream was injected into the chlorinator to chlorinate the donning surface of the glove. The chlorine concentration was 875 ppm and the pH was 1.8. The glove was immersed in the chlorine solution for 4 minutes. After chlorination, the glove was inverted and dried at a temperature of about 55° C. for 40 minutes.
- The latex glove was then dipped into a solution containing 96.725 wt. % water, 0.25 wt. % melamine-formaldehyde (crosslinking agent), 0.025 wt % of p-toluene sulfonic acid (a catalyst), and 3 wt. % of a hydrogel-forming polymer formed from hydroxy ethyl acrylate and acrylic acid monomers, which was obtained from Ortec, Inc. of Easley, S.C. The mixture was then heated to a temperature of about 120° C. for about 18 minutes to crosslink the polymer and form a hydrogel coating on the glove.
- To test the ability of the hydrogel-coated glove to controllably release an active agent, it was immersed for 7 hours in an aqueous solution containing 99.5 wt. % water and 0.5 wt. % of a dye (Fiber Identification Stain #7, available from Dupont). A comparative glove was also immersed for 7 hours in the same aqueous solution. The comparative glove was identical to the test glove, except that it did not contain a hydrogel coating. Each glove was removed from the dye solution and rinsed several times with water to remove excess dye. The gloves were then dried overnight in an oven at 60° C. Thereafter, 50 milliliters of water was injected into the hand-receiving cavity formed by each glove and allowed to remain for 2 minutes. The water was poured out, and an additional 50 milliliters of water was injected into the glove and allowed to remain for 3 minutes. This process was repeated with water being injected into the glove and allowed to remain for varying periods of time up to 280 minutes of contact time. The absorbance values of the water samples were then measured at a wavelength of 547 nanometers with a UV-visible spectrophotometer, which is commercially available from Shimadzu of Kyoto, Japan (Model No. UV-1601). The absorbance correlated with the amount of dye that had diffused out of the glove and into the water.
- The results are shown in
FIG. 3 . As indicated, an increased amount of the dye was detected for diffusion times ranging up to about 275 minutes. This exemplifies the ability of an active agent to be controllably released from a hydrogel coating present on a glove in accordance with the present invention. On the other hand, the glove that did not contain the hydrogel coating showed no ability to pick up the dye. - While the invention has been described in detail with respect to the specific embodiments thereof, it will be appreciated that those skilled in the art, upon attaining an understanding of the foregoing, may readily conceive of alterations to, variations of, and equivalents to these embodiments. Accordingly, the scope of the present invention should be assessed as that of the appended claims and any equivalents thereto.
Claims (41)
1. An elastomeric glove comprising:
a substrate body including a layer made of an elastomeric material, said substrate body defining an inner surface and an outer surface; and
a coating overlying the inner surface of said substrate body and defining a user-contacting surface of the glove, said coating comprising a crosslinked hydrogel network within which is retained an active agent capable of imparting a benefit to a user, wherein said active agent is releasable from said network when said coating is contacted with an aqueous environment.
2. An elastomeric glove as defined in claim 1 , wherein said elastomeric material of said substrate body is selected from the group consisting of styrene-ethylene-butylene-styrene block copolymers, styrene-isoprene-styrene block copolymers, styrene-butadiene-styrene block copolymers, styrene-isoprene block copolymers, styrene-butadiene block copolymers, natural rubber latex, nitrile rubbers, isoprene rubbers, chloroprene rubbers, polyvinyl chlorides, silicone rubbers, and combinations thereof.
3. An elastomeric glove as defined in claim 1 , wherein said elastomeric material of said substrate body is natural rubber latex.
4. An elastomeric glove as defined in claim 1 , wherein said hydrogel network is formed from one or more polymers, at least one of said polymers being formed from at least one monomer that is hydrophilic and water-soluble.
5. An elastomeric glove as defined in claim 4 , wherein said monomer is selected from the group consisting of vinyl pyrrolidones, hydroxyethyl acrylates, hydroxyethyl methacrylates, hydroxypropyl acrylates, hydroxypropyl methacrylates, acrylic acids, methacrylic acids, acrylic esters, methacrylic esters, vinyl pyridines, acrylamides, vinyl alcohols, ethylene oxides, derivatives thereof, and combinations thereof.
6. An elastomeric glove as defined in claim 4 , wherein said monomer is selected from the group consisting of hydroxyethyl acrylates, hydroxyethyl methacrylates, hydroxypropyl acrylates, derivatives thereof, and combinations thereof.
7. An elastomeric glove as defined in claim 1 , wherein said crosslinked hydrogel network is substantially water-insoluble.
8. An elastomeric glove as defined in claim 1 , wherein said crosslinked hydrogel network is capable of achieving a water content of from about 20% to about 90%.
9. An elastomeric glove as defined in claim 1 , wherein said crosslinked hydrogel network is capable of achieving a water content of from about 35% to about 85%.
10. An elastomeric glove as defined in claim 1 , wherein said crosslinked hydrogel network is capable of achieving a water content of from about 50% to about 80%.
11. An elastomeric glove as defined in claim 1 , wherein said active agent is a drug.
12. An elastomeric glove as defined in claim 1 , wherein said active agent is a skin-conditioner.
13. An elastomeric glove as defined in claim 1 , wherein said active agent is a botanical agent.
14. An elastomeric glove as defined in claim 1 , wherein the average thickness of said coating is from about 0.1 to about 20 micrometers.
15. An elastomeric glove as defined in claim 1 , wherein the coating comprises from about 0.001 to about 0.5 grams per gram of the glove.
16. An elastomeric article comprising:
a substrate body including a layer made of an elastomeric material, said elastomeric material being selected from the group consisting of styrene-ethylene-butylene-styrene block copolymers, styrene-isoprene-styrene block copolymers, styrene-butadiene-styrene block copolymers, styrene-isoprene block copolymers, styrene-butadiene block copolymers, natural rubber latex, nitrile rubbers, isoprene rubbers, chloroprene rubbers, polyvinyl chlorides, silicone rubbers, and combinations thereof, wherein said substrate body defines a surface; and
a coating overlying said surface of said substrate body, said coating comprising a substantially water-insoluble, crosslinked hydrogel network within which is retained an active agent capable of imparting a benefit, wherein said active agent is releasable from said network when said coating is contacted with water.
17. An elastomeric article as defined in claim 16 , wherein said elastomeric material of said substrate body is natural rubber latex.
18. An elastomeric article as defined in claim 16 , wherein said hydrogel network is formed from one or more polymers, at least one of said polymers being formed from at least one monomer that is hydrophilic and water-soluble.
19. An elastomeric article as defined in claim 18 , wherein said monomer is selected from the group consisting of vinyl pyrrolidones, hydroxyethyl acrylates, hydroxyethyl methacrylates, hydroxypropyl acrylates, hydroxypropyl methacrylates, acrylic acids, methacrylic acids, acrylic esters, methacrylic esters, vinyl pyridines, acrylamides, vinyl alcohols, ethylene oxides, derivatives thereof, and combinations thereof.
20. An elastomeric article as defined in claim 16 , wherein said crosslinked hydrogel network is capable of achieving a water content of from about 20% to about 90%.
21. An elastomeric article as defined in claim 16 , wherein said crosslinked hydrogel network is capable of achieving a water content of from about 50% to about 80%.
22. An elastomeric article as defined in claim 16 , wherein said active agent is a drug, skin-conditioner, botanical agent, or combination thereof.
23. An elastomeric article as defined in claim 16 , wherein the average thickness of said coating is from about 0.1 to about 20 micrometers.
24. An elastomeric article as defined in claim 16 , wherein the coating comprises from about 0.001 to about 0.5 grams per gram of the article.
25. A method for forming an elastomeric glove containing a substrate body and a coating overlying a surface of the substrate body, said method comprising:
dipping a hand-shaped former into at least one bath containing an elastomeric polymer to form the substrate body of the glove;
applying an aqueous solution to the substrate body or said hand-shaped former to form the coating of the glove, said aqueous solution containing at least one hydrogel-forming polymer and an active agent; and
crosslinking said hydrogel-forming polymer to form a substantially water-insoluble hydrogel network, wherein said active agent is retained within said hydrogel network, said active agent being releasable from said network when the coating is contacted with an aqueous environment.
26. A method as defined in claim 25 , wherein said aqueous solution is applied to the substrate body while present on said hand-shaped former.
27. A method as defined in claim 25 , wherein said aqueous solution is applied to the hand-shaped former prior to being dipped into said bath.
28. A method as defined in claim 25 , wherein said active agent constitutes from about 0.0001 wt. % to about 30 wt. % of said aqueous solution.
29. A method as defined in claim 25 , wherein said active agent constitutes from about 0.001 wt. % to about 10 wt. % of said aqueous solution.
30. A method as defined in claim 25 , wherein said hydrogel-forming polymer constitutes from about 0.1 wt. % to about 30 wt. % of said aqueous solution.
31. A method as defined in claim 25 , wherein said hydrogel-forming polymer constitutes from about 0.5 wt. % to about 10 wt. % of said aqueous solution.
32. A method as defined in claim 25 , wherein said aqueous solution further contains a crosslinking agent.
33. An method as defined in claim 25 , wherein said hydrogel-forming polymer is formed from at least monomer selected from the group consisting of vinyl pyrrolidones, hydroxyethyl acrylates, hydroxyethyl methacrylates, hydroxypropyl acrylates, hydroxypropyl methacrylates, acrylic acids, methacrylic acids, acrylic esters, methacrylic esters, vinyl pyridines, acrylamides, vinyl alcohols, ethylene oxides, derivatives thereof, and combinations thereof.
34. A method for forming an elastomeric glove containing a substrate body and a coating overlying a surface of the substrate body, said method comprising:
dipping a hand-shaped former into at least one bath containing an elastomeric polymer to form the substrate body of the glove;
applying an aqueous solution to the substrate body or said hand-shaped former to form the coating of the glove, said aqueous solution containing at least one hydrogel-forming polymer;
crosslinking said hydrogel-forming polymer to form a substantially water-insoluble hydrogel network; and
incorporating an active agent into said hydrogel network, said active agent being releasable from said network when the coating is contacted with an aqueous environment.
35. A method as defined in claim 34 , wherein said aqueous solution is applied to the substrate body while present on said hand-shaped former.
36. A method as defined in claim 34 , wherein said aqueous solution is applied to the hand-shaped former prior to being dipped into said bath.
37. A method as defined in claim 34 , further comprising applying an additional aqueous solution containing said active agent to said hydrogel network.
38. A method as defined in claim 34 , wherein said hydrogel-forming polymer constitutes from about 0.1 wt. % to about 30 wt. % of said aqueous solution.
39. A method as defined in claim 34 , wherein said hydrogel-forming polymer constitutes from about 0.5 wt. % to about 10 wt. % of said aqueous solution.
40. A method as defined in claim 34 , wherein said aqueous solution further contains a crosslinking agent.
41. An method as defined in claim 34 , wherein said hydrogel-forming polymer is formed from at least monomer selected from the group consisting of vinyl pyrrolidones, hydroxyethyl acrylates, hydroxyethyl methacrylates, hydroxypropyl acrylates, hydroxypropyl methacrylates, acrylic acids, methacrylic acids, acrylic esters, methacrylic esters, vinyl pyridines, acrylamides, vinyl alcohols, ethylene oxides, derivatives thereof, and combinations thereof.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/733,172 US20050132466A1 (en) | 2003-12-11 | 2003-12-11 | Elastomeric glove coating |
EP04777613A EP1691708A1 (en) | 2003-12-11 | 2004-07-06 | Elastomeric glove coating |
PCT/US2004/021611 WO2005060855A1 (en) | 2003-12-11 | 2004-07-06 | Elastomeric glove coating |
JP2006543789A JP2007524772A (en) | 2003-12-11 | 2004-07-06 | Elastic glove covering |
CA002545070A CA2545070A1 (en) | 2003-12-11 | 2004-07-06 | Elastomeric glove coating |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/733,172 US20050132466A1 (en) | 2003-12-11 | 2003-12-11 | Elastomeric glove coating |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050132466A1 true US20050132466A1 (en) | 2005-06-23 |
Family
ID=34677181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/733,172 Abandoned US20050132466A1 (en) | 2003-12-11 | 2003-12-11 | Elastomeric glove coating |
Country Status (5)
Country | Link |
---|---|
US (1) | US20050132466A1 (en) |
EP (1) | EP1691708A1 (en) |
JP (1) | JP2007524772A (en) |
CA (1) | CA2545070A1 (en) |
WO (1) | WO2005060855A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007142738A2 (en) * | 2006-05-31 | 2007-12-13 | Abbott Cardiovascular Systems Inc. | Coatings layers for medical devices and methods of making the same |
FR2910015A1 (en) * | 2006-12-18 | 2008-06-20 | Jean Loic Baratoux | Polymeric mixture for coating latex or plastic gloves, e.g. medical gloves, contains chitosan lactate, starch-based binder and acrylic polymer-based stabiliser |
US20100159035A1 (en) * | 2006-04-04 | 2010-06-24 | Avner Shemer | Kit for treating skin infection |
US20110099688A1 (en) * | 2009-07-08 | 2011-05-05 | Yvette Viva Saleh | Tea Extract Coated Glove |
CN104981504A (en) * | 2012-12-18 | 2015-10-14 | 安塞尔有限公司 | Fluid repellent elastomeric barrier |
CN104994890A (en) * | 2012-12-11 | 2015-10-21 | 创新创伤护理公司 | Hemostatic glove device and method for use of same |
WO2018119491A1 (en) | 2016-12-30 | 2018-07-05 | Skinprotect Corporation Sdn Bhd | Elastomeric articles having skin care properties and methods for their production |
WO2019133642A1 (en) * | 2017-12-27 | 2019-07-04 | Shen Wei (Usa) Inc. | Composition and methods for enhancing the application of materials on an elastomeric article and article thereof |
US10596790B1 (en) * | 2018-01-14 | 2020-03-24 | Fung Bor Chen | Multilayered elastomeric articles and methods thereof |
US10647886B2 (en) | 2015-10-18 | 2020-05-12 | Allegiance Corporation | Water-based hydrogel blend coating and method of application to elastomeric articles |
USD1009407S1 (en) * | 2021-06-24 | 2024-01-02 | InnovatioNxt, LLC | Elastomeric glove article with transparent portion |
WO2024219958A1 (en) * | 2023-04-20 | 2024-10-24 | Hartalega Research Sdn Bhd | Hydrogel coating formulation |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8137735B2 (en) * | 2005-11-10 | 2012-03-20 | Allegiance Corporation | Elastomeric article with antimicrobial coating |
US8353883B2 (en) | 2005-12-15 | 2013-01-15 | Kimberly-Clark Worldwide, Inc. | Elastomeric glove containing a foam donning layer |
Citations (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2976576A (en) * | 1956-04-24 | 1961-03-28 | Wichterle Otto | Process for producing shaped articles from three-dimensional hydrophilic high polymers |
US3411982A (en) * | 1964-03-18 | 1968-11-19 | Uniroyal Inc | Elastomeric article having a slip coating |
US3740262A (en) * | 1971-08-17 | 1973-06-19 | Dart Ind Inc | Dual finish surgeon's glove and method of making same |
US3784540A (en) * | 1971-10-05 | 1974-01-08 | Nat Patent Dev Corp | Process of preparing soluble hema-based polymers |
US3813695A (en) * | 1973-02-21 | 1974-06-04 | D Podell | Surgical glove |
US3992221A (en) * | 1975-10-23 | 1976-11-16 | Vitek, Inc. | Method of treating extensible hydrocarbon articles |
US4027060A (en) * | 1973-10-12 | 1977-05-31 | Sutures, Inc. | Rubber articles having improved slip coatings |
US4082862A (en) * | 1975-06-24 | 1978-04-04 | Sutures Inc. | Process for the production of rubber articles having improved slip coating |
US4192827A (en) * | 1974-06-27 | 1980-03-11 | Ciba-Geigy Corporation | Water-insoluble hydrophilic copolymers |
US4310928A (en) * | 1979-07-30 | 1982-01-19 | American Hospital Supply Corporation | Surgeon's glove and talc free process for forming same |
US4499154A (en) * | 1982-09-03 | 1985-02-12 | Howard L. Podell | Dipped rubber article |
US4597108A (en) * | 1984-11-28 | 1986-07-01 | Akira Momose | Powderfree surgical gloves |
US4851266A (en) * | 1988-05-31 | 1989-07-25 | Akira Momose | Surface treatment of powderfree surgical gloves |
US4853978A (en) * | 1987-07-24 | 1989-08-08 | Surgikos, Inc. | Antimicrobial medical glove |
US5003178A (en) * | 1988-11-14 | 1991-03-26 | Electron Vision Corporation | Large-area uniform electron source |
US5069965A (en) * | 1989-10-18 | 1991-12-03 | Bioresearch, Inc. | Articles having improved slip coatings |
US5084514A (en) * | 1990-11-14 | 1992-01-28 | Reichhold Chemicals, Inc. | Latex gloves with improved donnability |
US5112900A (en) * | 1990-11-28 | 1992-05-12 | Tactyl Technologies, Inc. | Elastomeric triblock copolymer compositions and articles made therewith |
US5160790A (en) * | 1990-11-01 | 1992-11-03 | C. R. Bard, Inc. | Lubricious hydrogel coatings |
US5284607A (en) * | 1991-11-22 | 1994-02-08 | Johnson & Johnson Medical, Inc. | Process for forming powder-free medical gloves |
US5300059A (en) * | 1991-11-19 | 1994-04-05 | Hydro Slip Technologies Inc. | Bloodbag and method of making same |
US5407715A (en) * | 1990-11-28 | 1995-04-18 | Tactyl Technologies, Inc. | Elastomeric triblock copolymer compositions and articles made therewith |
US5483697A (en) * | 1989-05-22 | 1996-01-16 | Board Of Regents The University Of Texas | Multilayer protective coverings with a sealing solution |
US5562646A (en) * | 1994-03-29 | 1996-10-08 | The Proctor & Gamble Company | Absorbent members for body fluids having good wet integrity and relatively high concentrations of hydrogel-forming absorbent polymer having high porosity |
US5742943A (en) * | 1996-06-28 | 1998-04-28 | Johnson & Johnson Medical, Inc. | Slip-coated elastomeric flexible articles and their method of manufacture |
US5776611A (en) * | 1996-11-18 | 1998-07-07 | C.R. Bard, Inc. | Crosslinked hydrogel coatings |
US5792531A (en) * | 1996-02-20 | 1998-08-11 | Tactyl Technologies, Inc. | Readily donned, powder free elastomeric article |
US5804318A (en) * | 1995-10-26 | 1998-09-08 | Corvita Corporation | Lubricious hydrogel surface modification |
US5817365A (en) * | 1991-04-22 | 1998-10-06 | Richardson; Margaret Pamela | Production of rubber articles, such as gloves |
US5900452A (en) * | 1996-08-12 | 1999-05-04 | Tactyl Technologies, Inc. | S-EB-S block copolymer/oil aqueous dispersion and its use in forming articles |
US5962995A (en) * | 1997-01-02 | 1999-10-05 | Applied Advanced Technologies, Inc. | Electron beam accelerator |
US5965276A (en) * | 1987-07-17 | 1999-10-12 | Bio Barrier, Inc. | Method of forming a membrane especially a latex or polymer membrane including multiple discrete layers |
US6017577A (en) * | 1995-02-01 | 2000-01-25 | Schneider (Usa) Inc. | Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices |
US6242042B1 (en) * | 1998-09-14 | 2001-06-05 | Lrc Products Ltd. | Aqueous coating composition and method |
US6306514B1 (en) * | 1996-12-31 | 2001-10-23 | Ansell Healthcare Products Inc. | Slip-coated elastomeric flexible articles and their method of manufacture |
US20020009561A1 (en) * | 1998-08-15 | 2002-01-24 | William Joseph Weikel | Lubricated elastomeric article |
US6407492B1 (en) * | 1997-01-02 | 2002-06-18 | Advanced Electron Beams, Inc. | Electron beam accelerator |
US6419913B1 (en) * | 1998-08-04 | 2002-07-16 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
US6524274B1 (en) * | 1990-12-28 | 2003-02-25 | Scimed Life Systems, Inc. | Triggered release hydrogel drug delivery system |
US6527990B2 (en) * | 2000-01-31 | 2003-03-04 | Hirono Chemical Ind. Co., Ltd. | Method for producing a rubber glove |
US20030056276A1 (en) * | 2001-08-27 | 2003-03-27 | Zimmerman Maryann B. | Dermal treatment applicator and method relating thereto |
US6562363B1 (en) * | 1997-09-26 | 2003-05-13 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
US6567693B1 (en) * | 1997-03-26 | 2003-05-20 | The Board Of Regents Of The University Of Oklahoma | Iontophoretic transdermal delivery device |
US20030118837A1 (en) * | 2001-12-21 | 2003-06-26 | Kimberly-Clark Worldwide, Inc. | Elastomeric gloves having improved donnability |
US6593292B1 (en) * | 1999-08-24 | 2003-07-15 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6610035B2 (en) * | 1999-05-21 | 2003-08-26 | Scimed Life Systems, Inc. | Hydrophilic lubricity coating for medical devices comprising a hybrid top coat |
US6630152B2 (en) * | 1999-04-07 | 2003-10-07 | Shen Wei (Usa), Inc. | Aloe vera glove and manufacturing method |
US6632457B1 (en) * | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
US6645181B1 (en) * | 1998-11-13 | 2003-11-11 | Elan Pharma International Limited | Drug delivery systems and methods |
US6743880B2 (en) * | 2000-03-31 | 2004-06-01 | Avery Denison Corporation | Hydrophilic polymers and methods of preparation |
US20040107477A1 (en) * | 2002-12-10 | 2004-06-10 | Kimberly-Clark Worldwide, Inc. | Crosslinking agent for coated elastomeric articles |
US20040266556A1 (en) * | 2003-06-27 | 2004-12-30 | Sullivan Michael J. | Pre-vulcanized or pre-crosslinked materials for golf balls |
US7041367B2 (en) * | 2003-06-03 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | Glove having improved donning characteristics |
US7175895B2 (en) * | 2003-11-19 | 2007-02-13 | Kimberly-Clark Worldwide, Inc. | Glove with medicated porous beads |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT77275B (en) * | 1982-09-03 | 1986-02-04 | Lrc Products | Rubber article with a lubricating layer and a process for the production thereof by dipping means |
GB9721679D0 (en) * | 1997-10-13 | 1997-12-10 | Lrc Products | Elastic thin-walled articles |
-
2003
- 2003-12-11 US US10/733,172 patent/US20050132466A1/en not_active Abandoned
-
2004
- 2004-07-06 CA CA002545070A patent/CA2545070A1/en not_active Abandoned
- 2004-07-06 EP EP04777613A patent/EP1691708A1/en not_active Withdrawn
- 2004-07-06 WO PCT/US2004/021611 patent/WO2005060855A1/en active Application Filing
- 2004-07-06 JP JP2006543789A patent/JP2007524772A/en not_active Abandoned
Patent Citations (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2976576A (en) * | 1956-04-24 | 1961-03-28 | Wichterle Otto | Process for producing shaped articles from three-dimensional hydrophilic high polymers |
US3411982A (en) * | 1964-03-18 | 1968-11-19 | Uniroyal Inc | Elastomeric article having a slip coating |
US3740262A (en) * | 1971-08-17 | 1973-06-19 | Dart Ind Inc | Dual finish surgeon's glove and method of making same |
US3784540A (en) * | 1971-10-05 | 1974-01-08 | Nat Patent Dev Corp | Process of preparing soluble hema-based polymers |
US3813695A (en) * | 1973-02-21 | 1974-06-04 | D Podell | Surgical glove |
US4027060A (en) * | 1973-10-12 | 1977-05-31 | Sutures, Inc. | Rubber articles having improved slip coatings |
US4192827A (en) * | 1974-06-27 | 1980-03-11 | Ciba-Geigy Corporation | Water-insoluble hydrophilic copolymers |
US4082862A (en) * | 1975-06-24 | 1978-04-04 | Sutures Inc. | Process for the production of rubber articles having improved slip coating |
US3992221A (en) * | 1975-10-23 | 1976-11-16 | Vitek, Inc. | Method of treating extensible hydrocarbon articles |
US4310928A (en) * | 1979-07-30 | 1982-01-19 | American Hospital Supply Corporation | Surgeon's glove and talc free process for forming same |
US4499154A (en) * | 1982-09-03 | 1985-02-12 | Howard L. Podell | Dipped rubber article |
US4548844A (en) * | 1982-09-03 | 1985-10-22 | Howard I. Podell | Flexible coated article and method of making same |
US4575476A (en) * | 1982-09-03 | 1986-03-11 | Howard I. Podell | Dipped rubber article |
US4597108A (en) * | 1984-11-28 | 1986-07-01 | Akira Momose | Powderfree surgical gloves |
US5965276A (en) * | 1987-07-17 | 1999-10-12 | Bio Barrier, Inc. | Method of forming a membrane especially a latex or polymer membrane including multiple discrete layers |
US4853978A (en) * | 1987-07-24 | 1989-08-08 | Surgikos, Inc. | Antimicrobial medical glove |
US4851266A (en) * | 1988-05-31 | 1989-07-25 | Akira Momose | Surface treatment of powderfree surgical gloves |
US5003178A (en) * | 1988-11-14 | 1991-03-26 | Electron Vision Corporation | Large-area uniform electron source |
US5483697A (en) * | 1989-05-22 | 1996-01-16 | Board Of Regents The University Of Texas | Multilayer protective coverings with a sealing solution |
US5069965A (en) * | 1989-10-18 | 1991-12-03 | Bioresearch, Inc. | Articles having improved slip coatings |
US5160790A (en) * | 1990-11-01 | 1992-11-03 | C. R. Bard, Inc. | Lubricious hydrogel coatings |
US5084514A (en) * | 1990-11-14 | 1992-01-28 | Reichhold Chemicals, Inc. | Latex gloves with improved donnability |
US5407715A (en) * | 1990-11-28 | 1995-04-18 | Tactyl Technologies, Inc. | Elastomeric triblock copolymer compositions and articles made therewith |
US5112900A (en) * | 1990-11-28 | 1992-05-12 | Tactyl Technologies, Inc. | Elastomeric triblock copolymer compositions and articles made therewith |
US6524274B1 (en) * | 1990-12-28 | 2003-02-25 | Scimed Life Systems, Inc. | Triggered release hydrogel drug delivery system |
US5817365A (en) * | 1991-04-22 | 1998-10-06 | Richardson; Margaret Pamela | Production of rubber articles, such as gloves |
US5300059A (en) * | 1991-11-19 | 1994-04-05 | Hydro Slip Technologies Inc. | Bloodbag and method of making same |
US5284607A (en) * | 1991-11-22 | 1994-02-08 | Johnson & Johnson Medical, Inc. | Process for forming powder-free medical gloves |
US5562646A (en) * | 1994-03-29 | 1996-10-08 | The Proctor & Gamble Company | Absorbent members for body fluids having good wet integrity and relatively high concentrations of hydrogel-forming absorbent polymer having high porosity |
US6017577A (en) * | 1995-02-01 | 2000-01-25 | Schneider (Usa) Inc. | Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices |
US5804318A (en) * | 1995-10-26 | 1998-09-08 | Corvita Corporation | Lubricious hydrogel surface modification |
US5792531A (en) * | 1996-02-20 | 1998-08-11 | Tactyl Technologies, Inc. | Readily donned, powder free elastomeric article |
US5742943A (en) * | 1996-06-28 | 1998-04-28 | Johnson & Johnson Medical, Inc. | Slip-coated elastomeric flexible articles and their method of manufacture |
US5900452A (en) * | 1996-08-12 | 1999-05-04 | Tactyl Technologies, Inc. | S-EB-S block copolymer/oil aqueous dispersion and its use in forming articles |
US6288159B1 (en) * | 1996-08-12 | 2001-09-11 | Tactyl Technologies, Inc. | S-EB-S block copolymer/oil aqueous dispersion and its use in forming articles |
US5776611A (en) * | 1996-11-18 | 1998-07-07 | C.R. Bard, Inc. | Crosslinked hydrogel coatings |
US6306514B1 (en) * | 1996-12-31 | 2001-10-23 | Ansell Healthcare Products Inc. | Slip-coated elastomeric flexible articles and their method of manufacture |
US5962995A (en) * | 1997-01-02 | 1999-10-05 | Applied Advanced Technologies, Inc. | Electron beam accelerator |
US6407492B1 (en) * | 1997-01-02 | 2002-06-18 | Advanced Electron Beams, Inc. | Electron beam accelerator |
US6567693B1 (en) * | 1997-03-26 | 2003-05-20 | The Board Of Regents Of The University Of Oklahoma | Iontophoretic transdermal delivery device |
US6562363B1 (en) * | 1997-09-26 | 2003-05-13 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
US6419913B1 (en) * | 1998-08-04 | 2002-07-16 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
US6632457B1 (en) * | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
US20020009561A1 (en) * | 1998-08-15 | 2002-01-24 | William Joseph Weikel | Lubricated elastomeric article |
US6242042B1 (en) * | 1998-09-14 | 2001-06-05 | Lrc Products Ltd. | Aqueous coating composition and method |
US6645181B1 (en) * | 1998-11-13 | 2003-11-11 | Elan Pharma International Limited | Drug delivery systems and methods |
US6630152B2 (en) * | 1999-04-07 | 2003-10-07 | Shen Wei (Usa), Inc. | Aloe vera glove and manufacturing method |
US6610035B2 (en) * | 1999-05-21 | 2003-08-26 | Scimed Life Systems, Inc. | Hydrophilic lubricity coating for medical devices comprising a hybrid top coat |
US6593292B1 (en) * | 1999-08-24 | 2003-07-15 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
US6527990B2 (en) * | 2000-01-31 | 2003-03-04 | Hirono Chemical Ind. Co., Ltd. | Method for producing a rubber glove |
US6743880B2 (en) * | 2000-03-31 | 2004-06-01 | Avery Denison Corporation | Hydrophilic polymers and methods of preparation |
US20030056276A1 (en) * | 2001-08-27 | 2003-03-27 | Zimmerman Maryann B. | Dermal treatment applicator and method relating thereto |
US20030118837A1 (en) * | 2001-12-21 | 2003-06-26 | Kimberly-Clark Worldwide, Inc. | Elastomeric gloves having improved donnability |
US20040107477A1 (en) * | 2002-12-10 | 2004-06-10 | Kimberly-Clark Worldwide, Inc. | Crosslinking agent for coated elastomeric articles |
US7041367B2 (en) * | 2003-06-03 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | Glove having improved donning characteristics |
US20040266556A1 (en) * | 2003-06-27 | 2004-12-30 | Sullivan Michael J. | Pre-vulcanized or pre-crosslinked materials for golf balls |
US7175895B2 (en) * | 2003-11-19 | 2007-02-13 | Kimberly-Clark Worldwide, Inc. | Glove with medicated porous beads |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100159035A1 (en) * | 2006-04-04 | 2010-06-24 | Avner Shemer | Kit for treating skin infection |
WO2007142738A2 (en) * | 2006-05-31 | 2007-12-13 | Abbott Cardiovascular Systems Inc. | Coatings layers for medical devices and methods of making the same |
WO2007142738A3 (en) * | 2006-05-31 | 2008-03-20 | Abbott Cardiovascular Systems | Coatings layers for medical devices and methods of making the same |
US8568764B2 (en) | 2006-05-31 | 2013-10-29 | Advanced Cardiovascular Systems, Inc. | Methods of forming coating layers for medical devices utilizing flash vaporization |
US8828418B2 (en) | 2006-05-31 | 2014-09-09 | Advanced Cardiovascular Systems, Inc. | Methods of forming coating layers for medical devices utilizing flash vaporization |
US9180227B2 (en) | 2006-05-31 | 2015-11-10 | Advanced Cardiovascular Systems, Inc. | Coating layers for medical devices and method of making the same |
FR2910015A1 (en) * | 2006-12-18 | 2008-06-20 | Jean Loic Baratoux | Polymeric mixture for coating latex or plastic gloves, e.g. medical gloves, contains chitosan lactate, starch-based binder and acrylic polymer-based stabiliser |
US20110099688A1 (en) * | 2009-07-08 | 2011-05-05 | Yvette Viva Saleh | Tea Extract Coated Glove |
CN104994890A (en) * | 2012-12-11 | 2015-10-21 | 创新创伤护理公司 | Hemostatic glove device and method for use of same |
CN104981504A (en) * | 2012-12-18 | 2015-10-14 | 安塞尔有限公司 | Fluid repellent elastomeric barrier |
US11577009B2 (en) * | 2015-10-18 | 2023-02-14 | Allegiance Corporation | Water-based hydrogel blend coating and method of application to elastomeric articles |
US10647886B2 (en) | 2015-10-18 | 2020-05-12 | Allegiance Corporation | Water-based hydrogel blend coating and method of application to elastomeric articles |
US12214108B2 (en) | 2015-10-18 | 2025-02-04 | Allegiance Corporation | Water-based hydrogel blend coating and method of application to elastomeric articles |
US11207250B2 (en) | 2016-12-30 | 2021-12-28 | Skinprotect Corporation Sdn Bhd | Elastomeric articles having skin care properties and methods for their production |
WO2018119491A1 (en) | 2016-12-30 | 2018-07-05 | Skinprotect Corporation Sdn Bhd | Elastomeric articles having skin care properties and methods for their production |
US11896690B2 (en) | 2016-12-30 | 2024-02-13 | Skinprotect Corporation Sdn Bhd | Elastomeric articles having skin care properties and methods for their production |
WO2019133642A1 (en) * | 2017-12-27 | 2019-07-04 | Shen Wei (Usa) Inc. | Composition and methods for enhancing the application of materials on an elastomeric article and article thereof |
US10596790B1 (en) * | 2018-01-14 | 2020-03-24 | Fung Bor Chen | Multilayered elastomeric articles and methods thereof |
USD1009407S1 (en) * | 2021-06-24 | 2024-01-02 | InnovatioNxt, LLC | Elastomeric glove article with transparent portion |
WO2024219958A1 (en) * | 2023-04-20 | 2024-10-24 | Hartalega Research Sdn Bhd | Hydrogel coating formulation |
Also Published As
Publication number | Publication date |
---|---|
CA2545070A1 (en) | 2005-07-07 |
JP2007524772A (en) | 2007-08-30 |
WO2005060855A1 (en) | 2005-07-07 |
EP1691708A1 (en) | 2006-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1691709B1 (en) | Method for forming an elastomeric article | |
US20050132466A1 (en) | Elastomeric glove coating | |
US20040122382A1 (en) | Elastomeric articles with beneficial coating on a surface | |
AU2005338646B2 (en) | Glove with hand-friendly coating and method of making | |
KR101941027B1 (en) | Nonaqueous coating composition for elastomeric articles and articles containing the same | |
US7776368B2 (en) | Gloves containing dry powdered aloe and method of manufacturing | |
US20050222543A1 (en) | Skin-care protective gloves and manufacturing method | |
CN113874427A (en) | Polymer system coating for elastic rubber gloves | |
US8695119B2 (en) | Coated elastomeric article and method for making a coated elastomeric article | |
MXPA06006486A (en) | Elastomeric glove coating | |
WO2004043235A2 (en) | Disposable gloves with allatoin | |
US7341962B2 (en) | Less irritant or inflammatory glove and method for producing the same | |
US20220175068A1 (en) | Damp Hand Donning and Moisturizing Glove | |
MXPA06006487A (en) | Method for forming an elastomeric article | |
MX2008006880A (en) | Glove with hand-friendly coating and method of making | |
WO2003084327A1 (en) | Aloe vera glove and manufacturing method | |
CA2441631A1 (en) | Aloe vera glove and manufacturing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KIMBERLY-CLARK WORLDWIDE, INC., WISCONSIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JANSSEN, ROBERT A.;JOHNSON, DAVID W.;MAYBERRY, PAM;REEL/FRAME:015311/0397;SIGNING DATES FROM 20040406 TO 20040412 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |